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Polycyclic aromatic hydrocarbons 
(PAHs), like benzo(a)pyrene (BP), 
are carcinogenic compounds present 
in tobacco smoke, which may 
increase the risk of breast cancer. 
Human breast cancer cell lines were 
characterized and BP-induced p53-
mediated responses protecting from 
the carcinogenic effects of BP in 
these cell lines were studied. The 
hypothesis that exposure to PAHs is 
one of the risk factors for breast cancer 
is supported by the formation of BP-
diolepoxide-DNA adducts, induction 
and activation of p53 protein  and the 
evidence of apoptotic cell death after 
BP-treatment. 
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ABSTRACT
Breast cancer is the most common cancer in women and there are indications that tobacco
smoke may increase the risk of this disease. This proposal is supported by epidemiological
data and studies in experimental animals. Tobacco smoke contains polycyclic aromatic
hydrocarbons (PAHs) which are formed during incomplete combustion of organic material.
Benzo(a)pyrene  (BP)  belongs  to  the  PAHs  and  it  has  been  used  as  a  model  compound  of
PAHs.
The aim of this study was to clarify the BP-induced p53-mediated responses protecting cells
from the carcinogenic  effects  of  BP in  human breast  cancer  cell  lines.  First,  the  TP53 gene
from five different cell lines was sequenced for the presence of mutations, and the ability of
the cells to metabolize BP was studied. In order to be active, p53 protein has to be post-
translationally modified e.g. phosphorylated or acetylated, in certain amino acids. p53
protein induction and phosphorylation were studied after BP treatment and the
characteristics of BP-induced cell death were also evaluated. The results in five different
breast cancer cell lines were compared to determine whether the responses of BP were
breast tissue specific or cell line specific.
Four of the five studied breast cancer cell lines formed benzo(a)pyrene-diol-epoxide-DNA
(BPDE-DNA)  adducts,  indicative  of  functional  metabolism  of  BP.  Two  of  the  cell  lines
contained a wild type TP53 gene (wtTP53) which is a prerequisite if one wishes to study the
normal p53 pathway. When different types of p53 phosphorylations were examined, it was
found that phosphorylation at serine 392 was the first stabilizing modification after BP-
treatment in the breast cancer cell line containing wtTP53. In the other cell lines containing
mutated TP53, there was no clear evidence for phosphorylation at serine 392. However, the
presence of other phosphorylations revealed that mutated p53 can be phosphorylated. BP-
induced cell death was mediated, at least partly, through p53-dependent apoptosis at least
in MCF-7 cells and possibly also in ZR-75-1 cells. These findings are supported by the
changes in several apoptotic proteins after BP-treatment.
In conclusion, this work supports data from the literature for the presence of BPDE-DNA
adducts in breast tissue in vivo and for the formation of mammary tumors in experimental
animals after BP-treatment. The hypothesis that exposure to PAHs is one of the risk factors
for breast cancer is supported by the findings in the human breast cancer cell lines: 1)
formation of BPDE-DNA adducts after BP-treatment, 2) p53 protein induction and
phosphorylation which are evidence of p53 activation, and 3) induction of apoptotic cell
death which is believed to be an attempt to protect the tissue from the harmful effects of BP.
National Library of Medical Classification: QU 300, QZ 202, WP 870
Medical Subject Headings: Breast Neoplasms; Benzo(a)pyrene/toxicity; Polycyclic Hydrocarbons, Aromatic;
Tumor Suppressor Protein p53; Carcinogens/toxicity; Cell Line, Tumor; Cell Death; Apoptosis; Caspase 7;
Cytochromes; Protein Processing, Post-Translational; Phosphorylation; Risk Factors
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TIIVISTELMÄ
Rintasyöpä on naisten yleisin syöpä ja tupakoinnin oletetaan olevan yksi tämän taudin
riskitekijä. Tätä tukevat epidemiologiset tutkimukset sekä koe-eläimillä tehdyt tutkimukset.
Tupakan savu sisältää polysyklisiä aromaattisia hiilivetyjä (PAH), joita muodostuu
orgaanisen materiaalin epätäydellisen palamisprosessin aikana. Bentso(a)pyreeni (BP)
kuuluu PAH-yhdisteisiin ja sitä on käytetty näiden yhdisteiden malliaineena.
Tämän tutkimuksen tarkoituksena oli selvittää ihmisen rintasyöpä-solulinjoissa BP:n
aiheuttamia p53-proteiini-välitteisiä vasteita, jotka suojelevat soluja BP:n karsinogeenisilta
vaikutuksilta. Ensiksi selvitettiin onko rintasyöpäsolujen TP53 geenin eksoneissa 5-8
mutaatioita, sekä solujen kykyä metaboloida BP:ä. Aktivoituakseen p53 proteiinin tiettyihin
aminohappoihin lisätään translaation jälkeen esim. fosfo- tai asetyyliryhmiä. p53 proteiinin
lisääntymistä sekä fosforylaatiota selvitettiin BP-altistuksen jälkeen eri
rintasyöpäsolulinjoissa. BP:n aiheuttaman solukuoleman luonnetta tutkittiin myös.
Tuloksia vertailtiin viidessä eri rintasyöpäsolulinjassa, että selviäisi ovatko BP:n
aiheuttamat vasteet ominaisia rintakudokselle vai solulinja-spesifisiä.
Neljässä viidestä solulinjasta muodostui bentso(a)pyreeni-dioli-epoksidi-DNA (BPDE-
DNA) addukteja mikä osoitti, että BP metaboloituu näissä soluissa. Kahdessa solulinjoista
(MCF-7 ja ZR-75-1) oli villin tyypin TP53 geeni, mikä on edellytys normaalin p53
proteiinitien tutkimiselle. Fosforylaatiotutkimukset osoittivat, että seriini 392 fosforylaatio
on ensimmäinen stabiloiva muokkaus BP-käsittelyn jälkeen rintasyöpäsoluissa, joissa on
villin tyypin TP53 geeni. Muissa solulinjoissa, joissa oli mutatoitunut TP53 geeni, selvää
seriini 392 fosforylaatiota ei havaittu. Muita fosforylaatioita kuitenkin havaittiin mikä
osoitti, että mutatoitunut p53 fosforyloituu. BP:n aiheuttaman solukuoleman osoitettiin
olevan, ainakin osittain, p53-välitteistä apoptoosia MCF-7 ja mahdollisesti myös ZR-75-1
soluissa. Näitä tuloksia tukevat havaitut muutokset apoptoosiin liittyvissä proteiineissa BP-
altistuksen jälkeen.
Tämä väitöskirjatyö tukee aiemmin saatuja tuloksia, joissa on BP-altistuksen jälkeen
havaittu BPDE-DNA addukteja in vivo rintakudoksessa sekä rintakudoskasvaimia in vivo
koe-eläimillä. Hypoteesia siitä, että PAH-yhdisteet ovat yksi riskitekijä rintasyövän
syntymisessä tukevat saadut tulokset ihmisen rintasyöpäsoluilla: 1) BPDE-DNA adduktien
muodostuminen BP-altistuksen jälkeen, 2) p53 lisääntyminen ja fosforylaatio viitaten
aktivoitumiseen ja 3) apoptoottisen solukuoleman lisääntyminen suojaten soluja BP:n
haitallisilta vaikutuksilta.
Yleinen Suomalainen asiasanasto: rintasyöpä – riskitekijät; karsinogeenit; PAH-yhdisteet; syöpäsolut
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1 Introduction
Cancer is the leading global cause of death. The International Agency for Research on
Cancer (IARC) estimated that in 2008 it accounted for 7.6 million deaths. Breast cancer is
one of the most frequent types of cancer in women; other common forms are lung, stomach,
colorectal and cervical cancers (WHO, 2008; WHO, 2010). The incidence of female breast
cancer in sub-Saharan Africa, China and in Eastern Asian countries is low, less than 20/100
000. However, in Northern and Western Europe, North America, parts of South America
and Australia, the incidence is much higher, 80/100 000 (WHO, 2008). The incidence has
rapidly increased in the developing countries and slowly increased in the developed
countries over the past five decades. However, the mortality has leveled off in Europe and
the Americas, and is currently even waning. Nonetheless, every year about 500 000 women
die of breast cancer (WHO, 2008). Breast cancer in men is rare, accounting for less than 1 %
of all cancers in men (Johansen Taber et al. 2010). The known risk factors for female breast
cancer are family history of breast cancer, early age of menarche, late age of menopause,
nulliparity, older age at full term pregnancies and short lactating periods.
In addition to the well-known risk factors, life style factors may also have an influence on
breast cancer risk. The use of alcohol has been demonstrated to increase the risk for breast
cancer (Hamajima et al. 2002) and there are claims that unhealthy nutrition and tobacco
smoking also increase the risk (Li et al. 1996; Gorlewska-Roberts et al. 2002). People are
exposed to hundreds of different chemicals during their lives and the effects of
environmental factors, such as exposure to polycyclic aromatic hydrocarbons (PAHs), on
the development of breast cancer have been studied from the beginning of 1990’s. It is well
known that tobacco smoke contains carcinogenic PAH-compounds (IARC, 2004; Wogan et
al. 2004) and there are studies indicating that exposure to PAHs may increase the risk of
breast cancer (Li et al. 1996; Gorlewska-Roberts et al. 2002; for review, see Brody et al.
2007a). In addition, in some studies exposure to other environmental factors, including
polychlorinated biphenyls, has been associated with a higher risk of breast cancer (Rudel et
al. 2007).
PAHs are formed during incomplete combustion of organic material (e.g. forest fires, traffic
exhaust, tobacco smoking and food processing) and thus these compounds are ubiquitous
in  the  environment.  Humans  are  exposed  to  PAHs  mainly  through  tobacco  smoking,  via
their occupation, or from food and traffic. The best known PAH is benzo(a)pyrene (BP) and
in  scientific  research  it  is  widely  used  as  a  model  compound  for  the  other  PAHs.  IARC
(2010) has classified BP as a human carcinogen (IARC class 1). It is a pro-carcinogen i.e. it
has to be metabolized before it can cause harmful effects. There are several pathways
involved in the metabolism of BP (Xue and Warshawsky, 2005). The most important is the
pathway that leads to a 7,8-diol-9,10- epoxide which is a known genotoxic compound.
Chemical carcinogenesis is a long and complex process where different chemicals may
induce tumor development by derailing the normal function of the cell. DNA damage is the
first step in this process and inorder to become cancerous, cells must go through a
transition to malignancy and clonal expansion of the transformed cells, and to acquire
increasingly aggressive characteristics (Vogelstein and Kinzler, 1993; Poirier, 2004; WHO
2008). UV-light and -radiation can cause DNA damage directly by evoking DNA damage.
2However, typically chemical carcinogens (e.g. BP, Aflatoxin B) require metabolic activation
to their carcinogenic metabolites. Evidence for human chemical carcinogenesis already
appeared in the 18th century,  when  Sir  Percivall  Pott  found  that  scrotal  cancer  was  very
common in chimney sweeps (reviewed by Poirier, 2004) and conclusively in the 1950s when
Doll and Hill revealed the association between cigarette smoking and lung cancer (Doll and
Hill, 1950). Although knowledge about the cancer risk by various chemicals has increased,
the precise molecular mechanisms involved in chemical carcinogenesis are still
inadequately known. It is clear, however, that the p53 protein as a tumor suppressor plays
an important role in chemical carcinogenesis (Bjelogrlic et al. 1994; Rämet et al. 1995;
Hainaut and Vähäkangas, 1997).
Cell  death is  one way of  saving an organism from harmful  effects  of  carcinogens.  Several
forms of cell death are known: necrosis, autophagy and apoptosis being the best known
(Elmore, 2007; Orrenius et al. 2011). Although necrosis has been considered as a passive
form of cell death, it is now known that even necrosis can be regulated through several
genes or proteins (Kung et al. 2011). In addition to cell death, autophagy may also be a cell
survival mechanism where old and damaged cell material and organelles are degraded by
lysosomal hydrolases (Eskelinen and Saftig, 2009; Maiuri et al. 2010). Apoptosis is strictly
regulated and one of the regulators is p53 protein which is involved in apoptosis through
transcription-dependent and –independent mechanisms (Chipuk et al. 2005; Green and
Kroemer, 2009; Speidel, 2010).
p53 protein was discovered about 30 years ago and it was first thought to be an oncogene
(for reviews, see Harris, 1996; Oren and Rotter, 1999). More detailed studies on the
functions of p53 in human cells led to the understanding that it was actually a tumor
suppressor protein which protects cells from DNA-damage induced stress. Subsequently,
p53 protein has been considered a “guardian of the genome” (Lane, 1992) since it has been
shown  that  p53  has  important  protective  functions  within  cells.  It  is  involved  in  many
crucial functions e.g. cell cycle arrest, DNA repair, senescence and apoptosis, and
disturbances in these functions are characteristics of carcinogenesis. Therefore, p53 and
p53-associated signal transduction pathways may be common targets in chemical
carcinogenesis and for this reason, p53 pathway responses, especially in apoptosis, are
important targets of research. It is also important to study the effects in several cell models
and to characterize the cell lines used to clarify the crucial molecular features important in
the particular study.
32 Review of the Literature
2.1 BREAST CANCER
2.1.1 Breast cancer as a disease
Today breast cancer is the most common cancer suffered by women. The incidence of breast
cancer  is  much  higher  in  western  countries  than  in  Japan  (Minamoto  et  al.  1999).  Studies
involving emigrants from Japan to Western countries have revealed that the risk of breast
cancer increases already within one generation after emigration (Minamoto et al. 1999). This
suggests that the change in the exposure to environmental factors can influence the risk and
development of breast cancer (Minamoto et al. 1999). Although breast cancer incidence has
clearly increased during the last decades, mortality has remained unchanged or even
declined as evident in the Nordic countries (figure 1). This may be due to better and earlier
diagnostics of breast cancer and the development of more efficient therapies (WHO, 2008).
Figure 1. Breast  cancer  incidence  and  mortality  in  the  Nordic  countries  (age  0-85+).  World
standard  population  [ASR  (w)]  used  for  age  standardization  in  NORDCAN  (Permission  from
NORDCAN; Engholm et al. 2010; http://www.ancr.nu).
2.1.2 Molecular changes of breast cancer
Breast cancer is a heterogenous disease at both the clinical and molecular levels; it can be
divided into several different molecular subtypes according to different gene expression
profiles. The expressions of estrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) are molecular features already used for clinical
classification of breast cancer (Polyak, 2007). The so-called triple negative breast cancer
lacks  ER,  PR  and  HER2  expression.  This  breast  cancer  type  is  the  most  aggressive  with  a
poor prognosis because it responds only partially to chemotherapy (Ismail-Khan and Bui,
2010; Podo et al. 2010). Both genetic (mutation in e.g TP53, poly(ADP-ribose)polymerase, c-
Myc) and epigenetic changes promote breast carcinogenesis conferring specific molecular
features on the individual tumor. It has been claimed that resolving these molecular
changes could help to clarify the evolution of the disease and provide tools for more precise
drug therapy. (Polyak, 2007; Stingl and Caldas, 2007; Lopez-Garcia et al. 2010; Ismail-Khan
and Bui, 2010; Podo et al. 2010)
4A family history of breast cancer may indicate genetic susceptibility towards the disease. A
first degree relative, e.g. mother or sister, with a breast cancer doubles the risk for female
breast cancer (Ripperger et al. 2009). In the 1990s, the first two breast cancer susceptibility
genes, BRCA1 and BRCA2, were identified in families with a high breast cancer risk.
Approximately 5-10 % of breast cancer cases are related to BRCA1 and BRCA2 tumor
suppressor genes (Lux et al. 2006; Ripperger et al. 2009). Mutations in these genes may
result in perturbation of important cellular protective functions of the cells, like DNA repair
and transcriptional regulation (Gudmundsdottir and Ashworth, 2006). An inborn mutation
in BRCA1 increases the lifetime breast cancer risk by 57 % and in BRCA2 by 49 %.
However, the risk is even higher if another family member is diagnosed with breast cancer
before the age of 35 (Antoniou et al. 2003).
Mutations in the TP53 gene may be found in familial breast cancer patients but they are
relatively rare, being involved in less than 1 % of familial breast cancer cases (Lux et al.
2006). TP53 gene encodes the p53 protein which has important protective functions within
the cell (Hainaut and Vähäkangas, 1997). Breast cancer is also associated with syndromes
due  to  other  gene  mutations,  e.g.  Cowden  syndrome  (PTEN  mutations),  Peutz-Jeghers
syndrome (STK11 mutations) and hereditary diffuse gastric cancer syndromes (CDH1
mutations) (Turnbull and Rahman, 2008). The genes involved in these syndromes are
tumor suppressors inhibiting cancer development. In addition, there are genes
participating in the DNA repair process, e.g. ATM, CHEK2, BRIP1 and PALB2, and
mutations in these genes increase the risk of breast cancer. BRIP1 interacts with BRCA1,
and PALB2 with BRCA2 affecting the DNA repair function of BRCA proteins (Turnbull and
Rahman, 2008). Breast cancer susceptible genes and their functions are shown in table 1.
Table 1. Breast  cancer  susceptibility  genes  and  their  effect  on  relative  risk  of  breast  cancer
(Modified from Turnbull and Rahman, 2008; Campeau et al. 2008; Ripperger et al. 2009).
Mutated gene Normal function Relative increase of
breast cancer risk
BRCA1 DNA repair, transcriptional regulation > 10x
BRCA2 DNA repair, transcriptional regulation > 10x
TP53 cell cycle arrest, DNA repair, apoptosis > 10x
PTEN (phosphatase and tensin
homologue)
tumor suppressor, growth regulator 2-10x
STK11 (serine/threonine protein kinase
11)
inhibits cellular proliferation,
controls cell polarity
2-10x
CDH1 (Cadherin 1, E-cadherin) invasion suppressor, controls cell
polarity
2-10x
ATM (ataxia telangiectasia mutated) DNA repair,
p53 and BRCA1 phosphorylation
2-3x
CHEK2 (Checkpoint kinase 2) DNA repair, replication 2-3x
BRIP1 (BRCA1 interacting protein C-
terminal helicase 1)
DNA repair 2-3x
PALB2 (Partner and localizer of BRCA2) DNA repair 2-4x
PTEN – phosphatase and tensin homologue; STK11 – serine/threonine protein kinase 11;
CDH1 – Cadherin 1, E-cadherin; ATM – ataxia telangiectasia mutated; CHEK2 – Checkpoint
kinase 2; BRIP1 – BRCA1 interacting protein C-terminal helicase 1; PALB2 –  Partner  and
localizer of BRCA2
52.1.3 Etiology of breast cancer
In addition to genetic susceptibility, the chemical etiology of breast cancer is a topic of
intensive research. It is known that reproductive and hormonal factors increase breast
cancer risk. The common denominator is thought to be estrogen, the female hormone that is
essential for sexual development and for the function of female organs (ovaries and uterus).
A high level and longer exposure time to estrogen can increase the risk for breast cancer not
only by inducing cell  proliferation but  also  by other  mechanisms (for  a  recent  review,  see
Yaghjyan and Colditz, 2011).
Occupation
Certain occupations have been shown to increase the risk of breast cancer in women. The
cohort study by Pukkala and coworkers (2009) estimated cancer incidences by occupational
categories in the Nordic population up to 45 years. The study revealed that in women, the
occupational groups with the highest standardized incidence ratio (SIR) of breast cancer
were military personnel (1.57, 95 % CI 1.03-2.30), dentists, journalists, physicians,
administrators and artistic workers. Shift work has been classified as probably carcinogenic
to humans (class 2A) by IARC. Thus, epidemiological studies have revealed a link between
increased breast cancer risk with increasing years of shift work in women (Hansen, 2010).
Environmental and life style factors
It has been proposed that a healthy diet may reduce breast cancer risk (Brennan et al. 2010)
although there are also studies showing no connection between the high-fat “Western diet”
and increased breast cancer risk (Thomson and Thompson, 2009). Hilakivi-Clarke and co-
workers (1999) concluded that high dietary linoleic acid intake in rats could elevate
estrogen levels during gestation and thus increased the breast cancer risk in their offspring.
Alcohol consumption is also an etiologic factor in breast cancer (Hamajima et al. 2002;
Brennan et al. 2010). According to Hamajima and co-workers (2002) 4 % of the breast cancer
load in the developing countries is a consequence of alcohol use. Various chemicals (e.g.
benzene, PAHs, ethylene oxide, MX, certain pharmaceuticals) have been shown to cause
mammary gland tumors in animal studies (Rudel et al. 2007). In addition, there is
increasing evidence for associations between human breast cancer and polychlorinated
biphenyls, PAHs and organic solvents (Hansen 2000; Brody et al. 2007a, 2007b, 2008, Anand
et  al.  2008).  Tobacco  smoke  is  one  of  the  main  sources  of  PAH  exposure  for  humans
(Castaño-Vinyals et al. 2004).
Tobacco smoking
Millions of people voluntary expose themselves to tobacco smoke even though it is well
know  to  be  associated  with  many  cancers,  e.g.  lung,  mouth  and  bladder  cancer  (IARC;
2004). Furthermore, the incidence of smoking among young women is increasing. There is
evidence that exposure to tobacco smoke or to long-term secondhand smoke at a young age
increases the risk of premenopausal breast cancer (Bottorff et al. 2010). Breast tissue
develops during puberty, pregnancy and after delivery. These are very sensitive periods for
breast tissue and exposure to tobacco smoke at these critical times may have an impact in
breast cancer formation (Lash and Aschengrau, 1999; Okasha et al. 2003; Bottorff et al.
2010). In the literature, on one hand there are results that do not reveal a clear connection
between tobacco smoking and breast cancer (Hecht, 2002; Sagiv et al. 2009). On the other
hand, there are research results that suggest that environmental tobacco smoke is one of the
6risk factors for premenopausal breast cancer (see review by Miller et al. 2007). Animal
studies have also revealed that BP can induce mammary tumors (El-Bayoumy et al. 1995).
These conflicting results clearly demand further clarification.
2.2 CHEMICAL CARCINOGENESIS
2.2.1 Process of chemical carcinogenesis
Exposure to carcinogenic chemicals from multiple sources and by different exposure routes
undoubtedly  has  a  role  in  the  etiology  of  cancer.  It  is  known  that  carcinogenesis  is  a
prolonged process requiring that many alterations take place in target cells.
Epidemiological and animal studies are essential if one wishes to reveal the association
between  exposure  to  a  chemical  and  certain  types  of  cancer.  Both  in  vivo  and  in  vitro
studies,  in  turn,  can  help  to  clarify  the  mechanisms  of  action  involved  in  chemically-
induced carcinogenesis.
In humans, chemical carcinogenesis usually requires years, or tens of years from the
beginning of the exposure to the clinical appearance of the tumor. During this time, cells
become abnormal with the ability to divide uncontrollably, to invade adjacent tissues and
to metastasize (figure 2) (Wogan et al. 2004). Today, it is known that carcinogenesis is not as
unequivocal as was originally postulated, instead being a more complex multistep
multifactorial process (Irigaray and Belpomme, 2010). Studies in laboratory animals have
shown that different carcinogens, the dose of carcinogen and the time of administration are
important factors in chemically induced cancer (Pitot et al. 1991). Carcinogenesis has been
divided into three stages (initiation, promotion and progression) in order to provide a
simplified view of the process (for reviews see Luch, 2005; Irigaray and Belpomme, 2010).
Based on this paradigm, DNA damage is the critical event in the initiation stage. If the
DNA repair machinery does not repair the damage or cells with DNA damage are not
removed by apoptosis, a mutation may be created and cloned into daughter cells during
cell division. During the promotion stage, non-genotoxic substances induce cell
proliferation or prevent apoptosis leading to clonal expansion of the initiated cells. Finally,
in the progression stage, premalignant mutated cells transform into the fully malignant cell
phenotype. The typical characteristics of these cells are their high proliferation rate, and
ability to metastasize and induce angiogenesis (Hanahan and Weinberg, 2011).
Currently  it  is  believed  that  carcinogenesis  is  an  evolving  process  where  mutations  in
different genes (e.g. oncogenes, tumor suppressor genes) occurring at different times carry
the process forwards. The most frequently mutated gene in human cancer is the TP53 gene
which encodes the tumor suppressor p53 protein (Petitjean et al. 2007a). By analysing TP53
mutations, it has been noted that certain carcinogens induce mutations in specific codons in
the TP53 gene (for reviews, see Vähäkangas 2003a, 2003b). These specific fingerprints were
speculated as providing tools with which to investigate the human carcinogenesis process
attributable to specific mutagenic agents/chemicals/substances (Hainaut and Vähäkangas,
1997). However, very few examples exist (Vähäkangas, 2003a) where a specific mutation
spectrum can be associated with a particular carcinogen. Mutations in TP53 may lead to an
inactive protein (Minamoto et al. 1999), or a protein which functions partially or has even
gained new functions (Haupt et al. 1995; reviewed by Brosh and Rotter, 2009).
7Figure 2. The process of chemical carcinogenesis and processes preventing tumor formation
(Modified from Vähäkangas, 2003b; Wogan et al. 2004).
2.2.2 Molecular mechanisms
Carcinogenesis can occur through several mechanisms (figure 3). Basically these can be
divided into genotoxic and non-genotoxic mechanisms including, suppression of DNA
repair. Genotoxic carcinogens affect the genome (DNA, chromosome) leading to mutation
or chromosomal damage and eventually to cancer formation. Non-genotoxic carcinogens
may  alter  signal  transduction  in  other  ways  which  promote  carcinogenesis  (Luch,  2005;
Hanahan and Weinberg, 2011). BP and aflatoxin B1 are examples of genotoxic carcinogens
that after metabolic activation react with DNA forming DNA-adducts (Poirier, 2004). In
recent years, however, non-genotoxic mechanisms have been a topic of increasing interest
and new mechanisms are being identified and elucidated (for review, see Henkler and
Luch, 2011).
8Figure 3. Genotoxic and non-genotoxic effects of carcinogens, and characteristics of cancer
(Modified from Luch, 2005; Hanahan and Weinberg, 2011).
Reactive  oxygen  species  (ROS)  are  formed  endogenously  in  electron  transport  chain  of
mitochondria but also exogenous agents and metabolism produce free radicals (for reviews
see Chandra et al. 2000; Xue and Warshawsky, 2005). ROS can cause oxidative DNA
damage  or  they  can  create  DNA  strand  breaks  thus  being  carcinogenic  by  genotoxic
mechanism. In addition, ROS may affect carcinogenesis through non-genotoxic
mechanisms, by affecting the cellular signal transduction processes (for review, see Goetz
and  Luch,  2008).  ROS  may  activate  various  factors  involved  in  cell  survival,  e.g.
extracellular signal related kinases (ERK1/2), protein kinase B (Akt) and NF-B, which may
all promote carcinogenesis. However, ROS may also induce cell cycle arrest and apoptosis
through p38 kinase, p53 protein and c-jun N-terminal kinase (JNK), i.e. preventing
carcinogenesis (Goetz and Luch, 2008 and references therein).
Non-genotoxic induction of carcinogenesis may also occur through disruption of endocrine
signaling (Henkler and Luch, 2011). It has been observed that environmental pollutants, e.g.
polychlorinated biphenyls may evoke adverse hormonal effects. The incidence of hormone-
dependent  cancers  (e.g.  breast  and  ovarian)  has  increased  during  last  decades  perhaps
indicative  of  an  adverse  effect  of  endocrine-disrupting  chemicals  on  these  organs  (for
review see Diamanti-Kandarakis et al. 2009). In the 1970s diethylstilbestrol was used in
pregnant  women  to  prevent  miscarriage.  Later  an  increase  in  the  incidence  of  previously
rare,  vaginal  tumors  was  detected  in  young  daughters  and  this  was  traced  to  the  use  of
diethylstilbestrol  by the  mothers  during the  time of  pregnancy (Rubin,  2007).  Thus,  today
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receptors, are carcinogenic and teratogenic in humans (Henkler and Luch, 2011).
Kanwal and Gupta (2010) have defined epigenetics “as heritable changes in gene
expression activity and expression that occur without alteration in DNA sequences but
which are sufficiently powerful to regulate the dynamics of gene expression”.
Investigations on epigenetics and cancer have shown that DNA methylation, modification
of  histone  proteins  and  also  RNA-dependent  regulation  can  promote  carcinogenesis  at
several levels, e.g. initiation, promotion and progression (see review by Kanwal and Gupta,
2010). Genes involved in cell cycle e.g. p16INK4A and DNA repair e.g. MLH1, BRCA1 have
been shown to undergo early methylation and this is a process that silences these genes and
promotes the process of carcinogenesis (for a review, see Gronbaek et al. 2007). Despite the
current knowledge there is much work still needing to be done before the link between
epigenetics and tumor formation will be fully understood.
Apoptosis is a very important preventive factor of carcinogenesis by removing unwanted
cells and also tumor cells with DNA damage in a controlled way. However, it has been
reported that genotoxic, non-genotoxic and also epigenetic mechanisms may lead to
resistance of apoptosis (Kanwal and Gupta, 2010; Henkler and Luch, 2011). There are
several mechanisms mediating anti-apoptotic effects. If genotoxic substances have induced
mutations in TP53 then this can prevent the pro-apoptotic function of p53 (for review, see
Hanahan and Weinberg, 2011). Another mechanism is believed to be the activation of NF-
B, and phosphatidylinositol-3 kinase-Akt pathways that are involved in several essential
cell signaling pathways, e.g. inflammation and control of the cell cycle (Fresno Vara et al.
2004; Maeda and Omata, 2008) thus promoting carcinogenesis (Henkler and Luch, 2011). In
particular NF-B may function through target genes that include anti-apoptotic proteins,
e.g. Bcl-XL and inhibitor of apoptosis protein (Maeda and Omata, 2008). An epigenetic
event may silence genes involved in apoptosis, e.g. death-associated protein kinase
(DAPK), thus contributing resistance of apoptosis (Kanwal and Gupta, 2010).
2.2.3 Carcinogens
Carcinogens can be of exogenous or endogenous origin. Exogenous carcinogens are all
types of physical, chemical and biological agents, like UV-light, chemicals like BP and
viruses, i.e. agents which have the potential to cause cancer after entering the body through
respiratory, digestive, skin or other routes (Wogan et al. 2004; Irigaray and Belpomme,
2010). Some metals have also been shown to be carcinogenic, e.g. arsenic, cadmium,
chromium and lead (Irigaray and Belpomme, 2010; Wise and Wise, 2010). Endogenous
carcinogens can emerge from the normal cellular processes, e.g. metabolism or
mitochondrial function (Irigaray and Belpomme, 2010). Metabolites of estrogen have been
shown to have genotoxic properties (Yaghjyan and Colditz, 2011). Humans are also
exposed to estrogen exogenously, e.g. through hormone replacement therapy which has
been claimed to increase the risk of breast cancer (Rudel et al. 2007).
Carcinogens can be divided into direct and indirect carcinogens (Nebert and Dalton, 2006).
Direct carcinogens (e.g. ethylene oxide, anticancer drugs) can react with DNA immedeately
after they have entered the cell while indirect carcinogens (e.g. PAHs, N-nitrosamines)
require metabolic activation, mainly through CYP enzymes, to produce reactive mutagenic
and carcinogenic metabolites. It has been estimated that ~25 % of all carcinogens are direct,
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whereas ~75 % are indirect carcinogens (Luch, 2005; Nebert and Dalton, 2006). Carcinogens
can be also non-genotoxic i.e. compounds that do not react with DNA but alter the signal
transduction pathways which are important in carcinogenesis (for review, see Luch, 2005).
Genotoxic  and  non-genotoxic  mechansims  can  interfere  with  signal  transduction  e.g.
resulting in loss of proliferation control and resistance to cell death (Luch, 2005; Hanahan
and Weinberg, 2011; figure 3) leading to mutations and ultimately to cancer formation.
2.2.4 Exposure to polycyclic aromatic hydrocarbons (PAHs)
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental contaminants that
are formed during incomplete combustion of oil, gas, wood or other organic substances
such as tobacco or grilled food (Gelboin 1980, IARC 2010). They are found in the
atmosphere, soil, waterways and food products (IARC 2010). Thus, the exposure to PAHs is
unavoidable. The main exposure to PAHs occurs through breathing in tobacco smoke, but
food, air and occupation are also important. Absorption and exposure of PAHs occur
through the respiratory tract, gastrointestinal tract and skin (IARC, 2010). PAHs are
composed of two or more aromatic benzene rings fused together. The resulting structure is
a molecule where all carbon and hydrogen atoms lie in one plane. Naphthalene is formed
from two benzene rings fused together, and anthracene has three benzene rings (figure 4).
Previously it was thought that PAHs that have a simple structure are not carcinogenic.
However, it is now known that even naphthalene can be carcinogenic indicating that a
complex structure is not a prerequisite for the carcinogenicity of a PAH-compound (Saeed
et al. 2007). Chrysene, benzo(a)pyrene and dibenzo(a,l)pyrene are PAHs that have more
complex structures (figure 4).
Figure 4. Examples of structures of polycyclic aromatic hydrocarbons.
Tobacco  smoke  is  one  of  the  major  sources  of  PAH,  since  it  contains  numerous  PAHs
(IARC, 2004; Wogan et al. 2004). Consequences of tobacco smoking are significant: 30 % of
all human cancers are due to tobacco smoking (WHO, 2008). Epidemiological studies and
also studies on experimental animals have shown that tobacco smoke can cause lung, oral
cavity and bladder cancer (Hecht, 2003). In addition, smokeless tobacco (chewing tobacco
and oral snuff) contains also potent carcinogens and it has been shown to cause oral cancer
and probably also pancreatic cancer (IARC, 2004; Hecht, 2003). The amounts of different
PAHs in one cigarette varies from a few to tens of nanograms (e.g. 1.7-3.2 ng of
dibenzo(a,l)pyrene, 10-40 ng of benzo(a)pyrene, 20-70 ng of benzo(a)anthracene) and in
smokeless tobacco the amount of benzo(a)pyrene can be 0.1-90 ng/g tobacco product
(WHO, 2008). Studies on the tobacco smoke content have identified at least 60 different
carcinogens, including PAHs (IARC, 2004; Wogan et al. 2004; see table 2).
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Table 2. Known carcinogens in tobacco smoke (modified from IARC, 2004; Wogan et al. 2004).
Chemical class No. of compounds Representative carcinogens
PAH 14 benzo(a)pyrene, dibenz(a,h)anthracene
Nitrosamines 8 NNK, NNN
Aromatic amines 12 4-aminobiphenyl, 2-naphtylamine
Aldehydes 2 Formaldehyde, acetaldehyde
Phenols 2 Catechol
Volatile hydrocarbons 3 Benzene, 1,3-butadiene
Nitro compounds 3 Nitromethane
Other organics 8 Ethylene oxide, acrylonitrile
Inorganic compounds 9 Cadmium
Total 61
NNN – N’-nitrosonornicotine, NNK – 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone
Food products  can be  contaminated by PAH compounds through two pathways.  Grilling
and heating of meat-products generates PAH compound-containing smoke which covers
the food (IARC, 2010). The amount of PAHs in grilled food depends on the method,
temperature and duration of cooking (IARC, 2010). The other pathway occurs through
environmental sources like by-products of petroleum and coal-tar combustion which
contaminate food products with PAH compounds (IARC, 2010). Vegetables, fruits, dairy
products and other unprocessed food can be contaminated with PAHs deposited from the
atmosphere, and subsequent uptake from soil, water and sediment (Kazerouni et al. 2001;
Ramesh et al. 2004). In addition, the preservation technique (heating, smoking) increases
the concentration of PAHs in the food (Roth et al. 1998; Ramesh et al. 2004). Kazerouni and
co-workers (2001) have measured the levels of BP in different food products and examined
how different cooking methods influence the BP levels. They also estimated, using a special
questionnaire, BP-intake in the population. The conclusion was that the BP consumption is
40-60 ng/day and that highest BP intake comes from bread/cereal/grain products,
barbequed meat and from vegetables (Kazerouni et al. 2001). The levels of BP differ
significantly between different food items, e.g. in smoked fish 48.0  μg/kg (dry weight), in
cow milk 1.5 μg/kg (wet weight) and in fruits 0.014 μg/kg (wet weight) (Ramesh et al. 2004).
Occupational exposure to PAHs is also significant. IARC (2010) has listed different
industrial workers and their exposure to PAHs. Industries where workers are most exposed
to PAHs are coke oven workers, chimney sweeps, and workers in wood impregnation, tar
distillation, aluminum production and electrode manufacturing (IARC, 2010). Palli et al.
(2004) studied the incidence of male breast cancer in BRCA1/2 mutation carriers and noted
that  breast  cancer  was common in  truck drivers  who are  exposed to  high levels  of  PAHs.
They concluded that in subjects carrying BRCA1/2 mutations, PAHs may increase the risk
of breast cancer not only in men but also in women.
The acute toxicity of PAHs is low, but carcinogenicity is one of the most serious forms of
their chronic toxicity (IARC, 2010), in addition to immunosuppression (De Jong et al. 1999).
Metabolic activation of PAHs to carcinogenic products involves at least three enzyme-
mediated reactions (reviewed by Xue and Warshawsky, 2005). Oxidation of the double
bond is catalyzed by cytochrome P450 (CYP) enzymes producing an arene oxide which is
hydrolyzed by epoxide hydrolase (EH) into a dihydrodiol. Finally, CYP catalyzed oxidation
at the double bond adjacent to the diol generates the diol-epoxide. This ultimate
carcinogenic product can covalently bind to and damage DNA, and finally cause cancer
(Pelkonen and Nebert, 1982). In addition to the so-called bay region dihydrodiol epoxide
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pathway, reactive PAH metabolites capable of damaging cellular macromolecules, like
DNA  and  proteins,  are  also  formed  by  two  other  metabolic  pathways  (Xue  and
Warshawsky, 2005). In one of these pathways, radical cations of PAHs are formed through
one-electron oxidation catalyzed by P450 peroxidase (Xue and Warshawsky, 2005) and the
third pathway of PAH activation involves the formation of o-quinones catalyzed by
dihydrodiol dehydrogenases to yield ROS (Xue and Warshawsky, 2005).  The ROS formed
can also damage DNA (Flowers et al. 1997) or induce cell proliferation (Burdick et al. 2003)
and thus contribute to carcinogenesis.
2.2.5 Benzo(a)pyrene (BP)
Pentacyclic BP (CAS 50-32-8) was isolated from coal tar in 1930 and its carcinogenicity was
initially demonstrated when it was repeatedly painted on mouse skin (for review, see Luch,
2005).  Today  BP  is  classified  as  human  carcinogen  by  several  agencies  (IARC,  EPA,  NTP,
ATSDR) (Castaño-Vinyals et al. 2004). BP is metabolically activated to its mutagenic and
carcinogenic metabolites (Pelkonen and Nebert 1982) of which the diol epoxide is the most
carcinogenic (figure 5). The aryl hydrocarbon receptor (AhR) is involved in the metabolism
of PAHs. Binding of BP to the Ah-receptor leads to the nuclear translocation of the complex
and its heterodimerization with ARNT/HIF1 (aryl hydrocarbon receptor nuclear
translocator/hypoxia induced factor 1). Finally this complex binds to xenobiotic-
responsive elements which are present in the promoter area of several genes e.g.  CYP1A1
and CYP1B1 enzymes leading to  their  expression.  Thus,  BP increases  its  own metabolism
through CYP activation and thus enhances the formation of the genotoxic metabolites
(Nebert et al. 2000; Fujii-Kuriyama and Mimura, 2005; Dietrich and Kaina, 2010).The
ultimate carcinogen is BP-7,8-diol-9,10-epoxide (BPDE) where the epoxide structure
covalently binds to DNA. The most common adduct is formed with N2 of deoxyguanosine
(BPDE-dG adduct).
Figure 5. Metabolism of benzo(a)pyrene by the dihydrodiol epoxide pathway. The figure shows
the numbering of the benzo(a)pyrene coal atoms and the bay region (arrow) where diol epoxide
is formed. BPDE-dG adduct is formed in the 10th carbon atom.
The effects of benzo(a)pyrene
BP has been rather extensively studied in animal and cell experiments and demonstrated to
possess  many effects  at  the  molecular  level  (table  3).  Due to  their  potential  to  cause  DNA
damage  and  harm  the  immunological  system,  BP  and  its  metabolites  can  affect  several
cellular processes leading to carcinogenesis and probably also immunosuppression. In
addition, other effects have also been described including epigenetic modification, cell cycle
changes, inappropriate cell death and survival, disturbed metabolism and gene expression.
BP has been shown to have immunosuppressive properties in animals (De Jong et al. 1999)
and  these  effects  can  also  be  observed  in  cell  experiments  (Allan  et  al.  2006;  Allan  and
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Sherr, 2010). The effects are thought to be mediated via AhR affecting lymphocyte
development and activation (Allan and Sherr, 2010 and references therein). Animal studies
with rats and mice have revealed several such alterations e.g. decreased weight of thymus
and disturbed B-cell distribution in the spleen, as well as other changes in immune-related
parameters (De Jong et al. 1999). Allan and Sherr (2010) developed an in vitro system and
demonstrated that the treatment of the human B cells with BP suppressed the
differentiation of these cells into plasma cells. The immunosuppressive effects of BP may
contribute also to carcinogenesis by impairing the defense of immune system e.g. against
tumor cells.
Table 3. Effects of benzo(a)pyrene in animal and cell experiments.
Target/Effect Typical molecular changes References
Genotoxicity,
mutagenicity:
DNA, Chromosomes,
Oncogenes, Tumor
suppressor genes
DNA-adducts, DNA damage,
chromosomal aberrations, mutations
in e.g. TP53 gene
Rämet et al. 1995;
Tapiainen et al. 1996;
Vähäkangas, 2003b; IARC, 2010;
Sigounas et al. 2010;
Jiang et al. 2010
ROS: Oxidative stress DNA damage,
Cell proliferation
Flowers et al., 1997;
Burdick et al. 2003
Epigenetic
modifications:
DNA methylation,
Histone acetylation
DNA hyper- and hypomethylation,
Histone hyper- and hypoacetylation
Sadikovic and Rodenhiser, 2006;
Sadikovic et al. 2008;
Tommasi et al. 2010
Cell cycle changes:
Cell proliferation,
S arrest, G2/M arrest
Loss of cell proliferation, accumulation
in S and G1/M phases
Solhaug et al. 2005; Drukteinis et al.
2005; Hockley et al. 2006; Sadikovic
and Rodenhiser, 2006; Andrysik et al.
2006; Caino et al. 2007;
Apoptosis Internucleosomal DNA fragmentation,
caspase activation, SubG1 increase,
cytochrome c release from
mitochondria, Bid cleavage
Solhaug et al. 2004a, 2004b, 2005;
Ko et al. 2004; Kim et al. 2005;
Sadikovic and Rodenhiser, 2006;
Chung et al. 2007; Holme et al. 2007
Necrosis Morphological changes of cell, PARP-1
activation, NAD+ depletion, p38-p53
signaling cascade, PI and PI/Hoechst
staining
Solhaug et al. 2005;
Lin and Yang, 2008;
Lin et al. 2008; Jiang et al. 2010;
Ovrevik et al. 2010
Cell survival Akt and ERK induction Solhaug et al. 2004b, 2005
Metabolism:
Ah-receptor
CYP enzyme or mRNA (CYP1A1,
CYP1B1) induction
Nebert et al. 2000;
Holme et al. 2007; Chung et al. 2007;
Topinka et al. 2008
Immunosuppression:
Immune system
Inhibition of B cell proliferation and
differentiation
De Jong et al. 1999; Allan et al.
2006; Allan and Sherr, 2010
Gene expression*:
Metabolism, apoptosis,
cell cycle, DNA repair,
chromatin assembly,
oxidative stress response
Up-regulation of xenobiotic
metabolism,
Up-regulation of genes associated
with cell cycle arrest and DNA repair,
repression of histone genes
expression, down-regulation of DNA
packaging and chromatin
assembly/disassembly
Hockley et al. 2006; 2007
*for further details see the references
Animal studies have shown that BP is metabolized to BPDE, and BPDE-DNA adducts are
formed (Bjelogrlic et al. 1994; Tapiainen et al. 1996; Serpi et al. 1999). BPDE-DNA adduct
formation can also be demonstrated in cell culture experiments (e.g. Rämet et al. 1995;
Melendez-Colon et al. 2000; Holme et al. 2007; Topinka et al. 2008). These studies have
highlighted the importance of BP metabolism as a prerequisite for its harmful effects. In
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addition, BPDE-DNA adducts have been measured from populations occupationally
exposed to BP (Rojas et al. 1995; Pavanello et al. 1999; IARC, 2010), from the sperm of
tobacco smokers (Sipinen et al. 2010) and from breast tissue from breast cancer patients (Li
et al. 1996). If the adducts are not removed and DNA is not repaired, this may result in the
generation of mutations and cancer. In addition, ROS, including superoxide (O2•-), hydroxyl
radical (OH•) and hydrogen peroxide (H2O2), and also other reactive metabolites can be
formed  during  BP  metabolism.  BP-induced  ROS  production  may  enhance  the
carcinogenicity of BP (for a review, see Xue and Warshawsky, 2005) since increased ROS
levels can damage the DNA, e.g. causing DNA strand breaks, (Flowers et al. 1997) or
inducing cell proliferation (Burdick et al. 2003).
In addition to genetic changes, BP may also affect cellular functions through epigenetic
mechanisms that include DNA methylation and histone acetylation both of which are
important in the regulation of many cellular functions (for reviews, see Reamon-Buettner et
al. 2008, Baccarelli and Bollati 2009). Hypermethylation of DNA may lead to suppression of
gene transcription. On the contrary, hypomethylation of DNA is associated with increased
gene transcription. Sadikovic and Rodenhiser (2006) studied the effect of BP on DNA
methylation in four different breast cancer cell lines and noted that BP could cause both
sequence-specific hyper- and hypomethylation of DNA. They also detected BP-induced
alterations in histone acetylation in MCF-7 cell line (Sadikovic et al. 2008). However,
Tommasi and coworkers (2010) studied the effect of BPDE in normal human fibroblast cells,
and they claimed that BPDE did not cause aberrant DNA methylation in these cells as
compared to control cells. Thus, further research is needed to clarify the issue of tissue-
specific mechanisms for BP-evoked epigenetic changes.
The effects of BP on cell cycle dynamics have been studied by several research groups (e.g.
Solhaug et al. 2005; Sadikovic and Rodenhiser, 2006; Andrysik et al. 2006). In human breast
cancer cell lines, BP causes loss of cell proliferation which is partly due to the accumulation
of cells in S and G2/M phases of cell cycle (Sadikovic and Rodenhiser, 2006). A similar effect
was reported by Drukteinis and coworkers (2005) in human placental choriocarcinoma
(JEG-3) cells. Accumulation of the cells in the S phase has been seen also in mouse and rat
cell lines (Solhaug et al. 2005; Andrysik et al. 2006). In addition, Caino and coworkers (2007)
reported that BP-7,8-dihydrodiol could inhibit cell proliferation in human bronchoalveolar
carcinoma (H358) cells. Furthermore, the metabolite of BP, BPDE, prevented induction of
G1 arrest effectively in human breast carcinoma (MCF-7) cells which meant that the
damaged DNA could progress to replication thus increasing the mutation frequency (Khan
and Dipple, 2000). One could argue that BP-induced cell cycle arrest provides time for DNA
repair. There are, however, situations where the damage to the DNA is too massive, and
the cell death is the appropriate outcome.
Studies with rodent (Ko et al. 2004; Solhaug et al. 2004a; 2004b; 2005; Kim et al. 2005;
Andrysik et al. 2006; Holme et al. 2007; Chung et al. 2007; Topinka et al. 2008) and human
cell lines (Ogba et al. 2005; Pliskova et al. 2005; Sadikovic and Rodenhiser, 2006) have
revealed BP-induced pro-caspase cleavage, internucleosomal DNA fragmentation and
subG1-phase increase. All of these parameters are regarded as markers of apoptotic cell
death. Hockley and coworkers (2006, 2007) also reported that BP induced expression of
apoptosis related genes in human MCF-7 cells. BP has also been shown to cause necrotic
cell death in human hepatocarcinoma (HepG2) cells through PARP-1 activation and NAD+
depletion (Lin and Yang, 2008). Further studies by Lin and coworkers (2008) indicated that
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the necrosis induced by BP in human HepG2 cells may go through the p38 MAPK-p53
signaling cascade where p38 MAPK phosphorylates and thus activates p53 triggering
necrotic cell death. Necrotic cell death has been demonstrated in normal fetal lung
fibroblasts (MRC-5) and in human lung adenocarcinoma cells (H1299) (Jiang et al. 2010)
where BP markedly induced necrosis through a p53-independent pathway. In conclusion,
BP-induced cell death seems to have both apoptotic and necrotic features depending on the
experimental system being used (see table 3 for details).
2.3 CELL DEATH
2.3.1 Forms of cell death
Cell  death  is  an  essential  and  normal  event  in  tissues  and  organs.  Especially  during
embryogenesis, coordinated cell death is needed for proper development. Cell death is also
involved in different pathological conditions, e.g. cancer, as well as neurodegenerative and
immunological diseases. In tumorigenesis, elimination of mutated or abnormal cells is one
way of eliminating unwanted material, which means that cell death is important in tumor
suppression. Different forms of cell death have been described. The two typical forms of
cell death are necrosis and apoptosis (table 4) which in extreme cases are easy to
differentiate from each other. Autophagy is regarded as a form of cell death but it is also
involved in pro-survival pathways. There are also several other, atypical, cell death forms
(just to mention a few: mitotic catastrophe, anoikis, paraptosis, entosis) (for detailed
reviews, see Kroemer et al. 2009; Yuan and Kroemer, 2010).
Necrosis has been traditionally described as an inappropriate and uncontrolled cell death.
Necrosis  can  occur  when  the  damage  to  the  cells  or  tissues  is  massive.  However,  studies
have shown that necrosis can also be regulated through a set of signal transduction
pathways as well as through catabolic mechanisms. Thus, necrosis may be programmed in
terms of both its course and occurrence (for reviews, see Golstein and Kroemer, 2006;
Kroemer et al. 2009; Kung et al. 2011). A new term for this programmed necrosis is
necroptosis (for review, see Yuan and Kroemer, 2010). Necrosis, or necroptosis, has been
shown to be activated by death domain receptors and Toll-like receptors which are
dependent on the kinase RIP1 (Holler et al. 2000). In addition, inhibition of apoptosis and
autophagy induces necrosis in immortalized baby mouse kidney epithelial cells
(Degenhardt et al. 2006). Caspases are the main regulators of apoptosis and the inhibition of
these enzymes has been shown to induce necrosis (Chautan et al. 1999; Cande et al. 2002;
Golstein and Kroemer, 2005). Thus, it can be said that necrosis can substitute for failed
apoptosis. Apoptotic necrosis occurs when apoptotic bodies are not eliminated by
phagocytosis (Fink and Cookson, 2005) indicating that the line between necrosis and
apoptosis is very thin. In  autophagy,  degrading  cytoplasmic  materials  (proteins,
old/damaged organelles) create double-membraned autophagosomes. These are fused with
lysosomes generating auto(phago)lysosomes where the content is degraded by lysosomal
hydrolases and the macromolecules are recycled to support cellular metabolism. Cells may
die with an autophagic morphology but autophagy promotes also cell survival (Eskelinen
and Saftig, 2009; Kroemer et al. 2009; Maiuri et al. 2010). In physiological terms, autophagy
occurs in several tissues to ensure the appropriate elimination of senescent and damaged
cell components. Even though autophagy may be a cell death pathway, its principal role is
to increase survival of the organism.
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Table 4. Forms of cell death and some of their morphological and biochemical features (Modified
from Kroemer et al. 2009; Orrenius et al. 2011).
Cell death Typical morphological features Typical biochemical features
Necrosis Cytoplasmic swelling.
Rupture of plasma membrane.
Swelling of cytoplasmic organelles.
Moderate chromatin condensation.
Activation of calpains and cathepsins.
Drop of ATP levels.
Specific PARP1 cleavage pattern.
RIP1 phosphorylation.
Inflammation
Apoptosis Rounding-up of the cells.
Reduction of cellular and nuclear volume.
Nuclear fragmentation.
Plasma membrane blebbing.
Apoptotic bodies.
Activation of Bcl-2 family proteins.
Activation of caspases.
Mitochondrial membrane permeabilization.
Decrease in mitochondrial transmembrane
potential.
Lack of inflammation.
Autophagy Lack of chromatin condensation.
Massive vacuolization of the cytoplasm.
Autophagic vacuoles.
Little or no phagocytosis.
Beclin-1 dissociation from Bcl-2/XL
Dependency of specific AuTophaGy-related
gene (ATG) products.
2.3.2 Process of apoptosis
Apoptosis was first described by Kerr and coworkers in 1972. In this form of cell death,
cells are eliminated in a controlled way. Apoptosis is thought to contribute to fetal
development and also to tissue homeostasis (Kerr et al. 1972). However, knock-out mice
lacking  the  main  machinery  of  apoptosis  survive  embryonic  development  and  become
normal adult animals (Chautan et al. 1999; Lindsten and Thompson 2006) meaning that
there must be compensatory mechanisms in cells. The typical features of apoptosis (see
table 4) are nuclear shrinkage, internucleosomal DNA fragmentation and cell blebbing
which are consequences of caspase activation (reviewed by Kroemer et al. 2009). Several
factors can trigger apoptosis e.g. DNA damage, viral infections and lack of growth factors.
Caspases (cysteine dependent aspartate cleaving proteases) are in a central role in apoptosis
and their activation is usually considered as a specific biochemical feature for apoptosis
(Cohen, 1997; for reviews, see Elmore, 2007; Ola et al. 2011). However, it is known that
apoptosis can occur without caspase activation (Orrenius et al. 2011). Caspases are
expressed as inactive pro-enzymes and after activation by cleavage they can activate other
pro-caspases leading to the caspase cascade and ultimately cell death. Caspases have
proteolytic activity and can cleave proteins at an aspartic acid residue leading to the
morphological features of apoptosis. Fourteen different caspases have been identified and
ten of them are considered as major caspases (Cohen, 1997; Elmore, 2007; Ola et al. 2011).
These are the initiators (caspase-2, -8, -9, -10), the effectors or executioners (caspase-3, -6, -7)
and inflammatory caspases (caspase-1, -4, -5); of these, the initiators and effectors are
involved in the “traditional” apoptotic pathway where initiator caspases activate effector
caspases. In addition, effector caspases can be activated through other proteins and
proteases, e.g. cathepsin and calpain. The other four caspases (11, 12, 13, 14) have tasks in
specific situations of cell fate, not described here (see Elmore, 2007 and references therein).
Another biochemical feature of apoptosis is the internucleosomal DNA fragmentation
(DNA ladder). DNA is degraded into 180-200 base pair fragments through Ca2+- and Mg2+-
dependent endonucleases (for a review, see Bortner et al. 1995).
Apoptosis can be initiated through several signals from outside, as well as inside of the cell
and mediated through various signaling pathways (for review, see Orrenius et al. 2011).
Commonly, apoptosis is described as being either receptor or mitochondrion mediated but
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there are several other signaling pathways involved in apoptosis and to confuse the
situation totally, these signaling pathways may take part in each other’s regulation.
2.3.3 Molecular mechanisms of apoptosis
Receptor-mediated (extrinsic) apoptotic route
In this route, the initial signal comes from outside of the cell (see figure 6). The signal or the
death ligand in this case, binds to its specific receptor which has a cytoplasmic domain
called a “death domain” (for reviews, see Elmore, 2007; Orrenius et al. 2011; Ola et al. 2011)
which transmits the signal to intracellular signaling pathways. There are several ligand
(L)/receptor (R) pairs the best known being FasL/FasR and TNF-/TNFR1. Binding of the
ligand to the receptor leads to an association of the specific adapter protein FADD (Fas
associated death domain) in the cytoplasm. The receptor, its ligand, procaspase-8 and other
co-factors forms DISC (death-inducing signaling complex) which enables procaspase-8
activation, and finally caspase-3 and -7 activation. The receptor-mediated pathway can
activate the mitochondrial-mediated pathway through caspase-8 activation which can bind
to Bid and cleave it. The truncated Bid (tBid) prevents the function of anti-apoptotic Bcl-2
proteins and induces the activation of pro-apoptotic Bax and Bak proteins promoting
cytochrome c release and caspase-9 activation (Elmore, 2007; Chipuk and Green, 2008;
Orrenius et al. 2011).
Mitochondrial-mediated (intrinsic) apoptotic route
Initiation of the intrinsic apoptotic route does not require receptor binding. There are
several signals that can initiate the intracellular mitochondrial-mediated signaling pathway
e.g. free radicals,  viruses or DNA-damage produced by a carcinogen or radiation (Elmore,
2007; Ola et al. 2011). The ultimate effect in mitochondria triggered by these different
signals is the opening of the mitochondrial permeability transition pore and loss of
mitochondrial transmembrane potential. This leads to the release of pro-apoptotic
cytochrome c, Smac/DIABLO (second mitochondrial activator of caspase/direct IAP binding
protein with low PI) and serine protease HtrA2/Omi (high-temperature requirement) into
cytosol. These proteins activate caspases triggering apoptotic cell death. In particular,
cytochrome c binds Apaf-1 (apoptotic protease activating factor) and pro-caspase-9 proteins
in the presence of dATP which forms a protein complex called the apoptosome. Activation
of pro-caspase-9 leads to the activation of pro-caspase-3 and the whole caspase cascade
(Elmore, 2007; Orrenius et al. 2011; Ola et al., 2011; figure 6).
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Figure 6. The well-known receptor-  and mitochondrial-mediated apoptotic  routes.  FADD = Fas
associated  death  domain;  TNFR1  =  tumor  necrosis  factor  receptor  1;  Apaf-1  =  apoptotic
protease activating factor; PUMA = p53 upregulated modifier of apoptosis; tBid = truncated Bid
(Elmore, 2007; Speidel, 2010; Orrenius et al. 2011; Ola et al. 2011).
There are several proteins involved in the mitochondrial-mediated apoptosis. Many of
these proteins belong to the Bcl-2 family proteins which share similarities in their structure
(for a review, see Chipuk and Green, 2008). Anti-apoptotic proteins, e.g. Bcl-2, Bcl-XL, Mcl-
1,  all  have  four  Bcl-2  homology  (BH1-4)  domains,  whereas  pro-apoptotic  Bax  and  Bak
contain BH1-3 domains and PUMA and Noxa are BH3-only proteins. Anti-apoptotic Bcl-2
and Bcl-XL prevent apoptosis mainly at mitochondria by inhibiting mitochondrial outer
membrane permeabilization (MOMP) (review by Speidel, 2010) although they also have a
role in the cytoplasm. Pro-apoptotic proteins are located in the cytoplasm from where they
can move to the mitochondrial outer membrane leading to pore opening (Breckenridge and
Xue, 2004). p53 protein is involved in apoptosis at both the transcriptional and non-
transcriptional levels. In the nucleus, p53 regulates transcription of several genes encoding
pro-apoptotic proteins (for a review see e.g. Haupt et al. 2003, Hofseth et al. 2004; Vousden
and Lane, 2007), and in cytoplasm and mitochondria p53 can interact with both anti-
apoptotic and pro-apoptotic proteins to promote apoptosis (for reviews, see Green and
Kroemer, 2009; Speidel, 2010).
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PUMA
PUMA (p53  upregulated modifier of apoptosis) protein was found by three different
groups in 2001  through yeast two-hybrid screening (Han et al. 2001) and global gene
expression profiling (Nakano and Vousden, 2001; Yu et al, 2001) and it is recognized as an
important protein in apoptosis (Yu and Zhang, 2009). DNA damage induces PUMA
through  p53-dependent  transcription  although  p53-independent  induction  also  exists  (Yu
and Zhang, 2009). The PUMA gene has been shown to code for four different isoforms of
the protein, of which  and , containing the BH3 domain (Bcl-2  homology 3), are the
functional forms (Nakano and Vousden, 2001). The exact significance of  and  isoforms is
not understood and it is not known which is the major form responsible for apoptosis.
Nakano and Vousden (2001) speculated that both can induce apoptosis. However, it has
been known for some time that the BH3 domain is required for interactions of PUMA with
Bcl-2-like proteins, such as Bcl-2 and Bcl-XL (Nakano and Vousden, 2001; Yu et al, 2001).
The binding of PUMA to the anti-apoptotic proteins e.g. to Bcl-2 and Bcl-XL liberates p53,
Bax and Bak proteins (described as enabler). Ultimately p53, Bax and Bak increase
mitochondrial membrane permeability thus releasing free cytochrome c into the cytoplasm
leading to apoptosis (Chipuk et al. 2005, Yu and Zhang, 2009). There are also proposals that
PUMA  can  interact  directly  with  Bax  or  Bak  (described  as  an  activator)  promoting
apoptosis (Kim et al. 2006). However, Yee and Vousden (2008) in their study with U2OS
(human osteosarcoma) cells transfected with PUMA plasmids concluded that binding of
PUMA to Bax had a less important role in apoptosis. The other BH3-only protein, Noxa, is
also a transcriptional target of p53 protein and it has been postulated to assist or
complement the function of PUMA in apoptosis (Michalak et al. 2008; review by Yu and
Zhang, 2009). However, co-operation of PUMA and Noxa is probably dependent on the cell
types, apoptotic stimuli and status of other genes since PUMA alone has been shown to
contribute to apoptosis in mature T and B cells of mouse spleen (Michalak et al. 2008). Even
though the function of PUMA is usually dependent on cytoplasmic p53 protein, PUMA can
induce apoptosis also in a p53-independent manner (Chipuk et al. 2005; Chipuk and Green,
2009).
2.4 THE p53 TUMOR SUPPRESSOR
2.4.1 History of p53
The continuing interest in p53 is reflected in the increasingly prolific literature dealing with
this protein. By the summer of 2011, there were over 58 000 publications on p53 in PubMed
(http://www.ncbi.nlm.nih.gov/pubmed?term=p53). While much is known about p53, there
are  still  many questions  unanswered relating to  the  functions  of  p53 in  the  cell.  From the
carcinogenesis point of view, the basic function of the p53 protein is to protect the genome
from DNA damaging agents and thus from cancer. For this reason, it has been described
also as a “Guardian of the genome” (Lane, 1992).
p53 protein was found in 1979 when a 53 kDa protein was shown to bind to Simian Virus
40 (SV40) large T antigen (for reviews, see Harris, 1996; Oren and Rotter, 1999; Robins et al.
2007). In the beginning of 1980s, the gene was cloned from neoplastic rodent and human
cells  and  it  was  found  to  be  oncogenic.  Further  studies  showed,  however,  that  they  were
studying mutant p53 instead of the wild type protein. By the end of 1980s, Arnold Levine’s
group showed that the wt p53 protein can inhibit oncogenes in transformed cultured cells
and p53 behaves as a tumor suppressor. Finally, due to the fact that p53 protein could be
inactivated by binding to viral oncogene products, e.g. SV40 large T antigen and mutations
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in TP53 gene were associated with cancer formation, it was concluded that p53 was a tumor
suppressor (Robins et al. 2007).
2.4.2 TP53 gene
The human TP53 gene is localized on chromosome 17 p13.1 and the full gene contains 11
exons. Its role in tumor suppression has been confirmed in TP53-deficient mice where the
development seemed to be normal but the incidence for tumor formation high (Donehower
et  al.  1992).  In  humans,  the  importance  of  p53  has  also  been  revealed  in  Li-Fraumeni
syndrome families where a germline TP53 mutation predisposes the mutation carriers to
multiple forms of cancer e.g. soft tissue sarcomas, osteosarcomas and breast cancer
(Kleihues et al. 1997).
The TP53 gene is mutated in almost half of human cancers (Olivier et al. 2010) and it has
been estimated that 97 % of mutations occur in the DNA binding domain (Hainaut and
Hollstein, 2000; Olivier et al. 2002; McKinney and Prives, 2007), i.e. amino acids 102-292 of
the protein (see figure 8). Mutations in DNA binding site prevent p53 protein of binding to
DNA which inhibits the transcriptional activation of target genes (Joerger and Fersht, 2008).
Although some mutations can inactivate p53 protein, others may not change the function of
p53 at all (retained function). A mutation can also generate gain of function where the
function of p53 in cell has changed to being oncogenic (Petitjean et al. 2007b). Some
mutations of the TP53 gene, the so-called “hot-spots”, are associated with certain
carcinogens. For instance, AFB1 causes a G to T transversion in codon 249 which is
associated with AFB1-induced hepatocellular carcinoma and UV-light induces a change
from CC to TT in the TP53 gene. However, despite the initial promise that it would be
possible to use this as a kind of fingerprinting technique, very few specific TP53 mutations
or mutation spectrum due to other carcinogens have been found (for more details see a
review by Vähäkangas, 2003a).
The TP53 gene belongs to a family of genes which express three different members: p53,
p63 and p73. p63 and p73 have roles in development and differentiation (Marcel and
Hainaut, 2009). Both p63 and p73 have several isoforms that are generated through
multiple promoters and alternative splicing (Khoury and Bourdon, 2010). Their structure is
composed of a DNA-binding domain (DBD), similar to the DBD of p53, but with different
N- and C-termini. It has been known for some time that p63 and p73 have several isoforms
that lead to proteins with modified functions (Murray-Zmijewski et al. 2006). Currently it is
known that the human TP53 gene structure and mRNA processing allow for at least twelve
different p53 isoforms (Khoury and Bourdon, 2011).
p53 protein isoforms
p53 isoforms are formed through alternative splicing, alternative promoter usage and
alternative  initiation  sites  of  translation.  Most  of  the  isoforms  share  a  common  DNA-
binding domain but differ in their amino- and carboxy-terminal domains (figure 7)
(Bourdon et al. 2005; Khoury and Bourdon, 2011). p53 has been described in the literature
as one additional p53 isoform (Baumbusch et al. 2006). It is shortened by deletion of 66
amino acids at the end of DBD and the entire NLS preceeding the oligomerization domain
(see figure 7). However, whether or not this isoform actually exists is still an open question.
This so-called dual gene structure (encoding truncated proteins) has been conserved
21
through evolution which suggests that p53 isoforms may be important factors in p53 tumor
suppressor activity (Khoury and Bourdon, 2010; 2011).
Figure 7. Human  p53  isoforms.  FLp53  =  Full  length  p53;  TADI  and  TADII  =  transactivation
domains  I  and  II;  PR  =  proline  rich  domain;  DBD  =  a  central  DNA-binding  domain;  OD  =
oligomerization domain; BR = basic region. Nuclear localization signal (NLS) is shown as grey
box  before  OD.  Weight  of  the  protein  isoforms  are  shown  in  brackets  (kDa).  (Modified  from
Marcel and Hainaut, 2009; Khoury and Bourdon, 2010; Khoury and Bourdon, 2011).
Isoforms have different functions in cell. Some of the isoforms can modulate the
transcriptional activity of p53 but they may also have p53-independent activities. In
addition, they can possess p53-dependent but transcriptionally independent activities also
(reviewed by Marcel and Hainaut, 2009; Khoury and Bourdon, 2010). p53 is  a modulator
of p53 activity e.g. by enhancing p53 transcriptional activity on the Bax promoter and by
increasing p53-dependent induction of p21 leading to replicative cellular senescence
(Khoury and Bourdon, 2010). The expression of 133p53 has been shown to repress p53-
dependent apoptosis in H1299 cells, and 133p53  inhibited p53 transcriptional activity on
Bax and p21 promoters by dominant negative effect when 133p53 and full length p53
were co-transfected (Khoury and Bourdon, 2010). 40p53 appears to retaine the DNA-
binding and oligomerization capacity, being able to activate target genes and thus
functioning as a transcription factor (Ohki et al. 2007; Powell et al. 2008). However, due to
lack of transactivation domain I (TADI), the transcriptional activity is relatively weak (for
review, see Hafsi and Hainaut, 2011). 160p53 isoforms (,  and ) were found recently
and they are encoded by 133p53, 133p53 and 133p53 mRNAs, respectively, through
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alternative initiation of translation (Marcel et al. 2010). Although the functions of these
160p53 isoforms are still unclear, Marcel et al. (2010) suggests that 160p53 have a role in
erythroid differentiation.
2.4.3 p53 protein
TP53 gene encodes a 53 kDa phosphoprotein consisting of 393 amino acids in humans. The
structure  of  the  p53  protein  has  three  separate  domains:  amino-terminal,  central  DNA-
binding domain and carboxy-terminal domains (figure 8).
Figure 8. Domain organization of human p53 protein: N-terminal transactivation domains (TADI
residues 1-40; TADII residues 43-73); nuclear export signal (NES, residues 11-27); MDM2
binding  site  (residues  19-26);  proline  rich  domain  (PR  residues  65-97);  central  DNA-binding
domain (DBD residues 102-292); nuclear localization signal (NLS, residues 300-325); C-
terminal  oligomerization  domain  (OD residues  325-356);  nuclear  export  signal  (NES,  residues
340-351); basic region (residues 363-393) and nuclear localization signals (NLS, residues 369-
375 and 379-384). (According to Shaulsky et al. 1990; McKinney and Prives, 2007; Marcel and
Hainaut, 2009).
Transactivation domains are required for transactivation of target genes. Within the TADI
region there is a binding site for the negative regulator MDM2 or in human HDM2 (human
double minute 2), and acetyltransferase p300/CBP which is responsible for C-terminal
acetylation (for a review, see Joerger and Fersht, 2007, 2008). In addition, one nuclear export
signal (NES) is localized within TADI, residues 11-27 (Marcel and Hainaut, 2009). TADII
contains  the  proline-rich  domain  (PR)  which  is  thought  to  play  a  regulatory  role  (Joerger
and Fersht, 2007) and is involved in p53-mediated apoptosis (McKinney and Prives, 2007).
The DNA binding domain (DBD) is for specific DNA binding for the consensus sequence at
the promoter of target genes, and it harbours the most evolutionary conserved sequences in
the protein (Joerger and Fersht, 2007, 2008). C-terminal domain consists of oligomerization
domain  (OD)  and  a  basic  region.  OD  is  involved  in  the  regulation  of  the  tetramerization
state of p53 (homotetramer) which is required for activation of the protein (Joerger et al.
2007, Joerger and Fersht, 2008). OD contains also one nuclear localization signal (NLS,
residues 316-325) and one NES (residues 340-351) (McKinney and Prives, 2007). The basic
region, also known as a negative auto-regulatory domain, contains phosphorylation and
acetylation sites, and it interacts with DNA non-specifically (McKinney and Prives, 2007;
Joerger and Fersht, 2007). There are also two NLS in the basic region (see figure 8; Shaulsky
et al. 1990; McKinney and Prives, 2007).
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p53 can be localized to nucleus, cytoplasm and mitochondria (Hollstein and Hainaut, 2010).
In the nucleus, it acts as a transcription factor transactivating the genes involved in
apoptosis (PUMA, BAX), cell cycle regulation (p21, 14-3-3) and metabolism (TP53-induced
regulator of apoptosis and glycolysis, TIGAR) (Green and Kroemer, 2009). In cytoplasm,
p53 can induce apoptosis by both receptor- and mitochondria-mediated routes (Vousden
and Lane, 2007). In mitochondria, especially in outer mitochondrial membrane, p53 induces
mitochondrial outer membrane permeabilization (MOMP) through an interaction with Bax
or Bak, releasing the pro-apoptotic factors from the mitochondrial intermembrane space
(Green and Kroemer, 2009; Speidel, 2010). Haupt and coworkers (1995) have shown that
mutant  p53  which  lacks  a  large  part  of  the  DBD  and  is  thus  deficient  in  transactivating
genes responsive to wt p53, was able to induce apoptosis in HeLa cells. That study
indicated that even though p53 was unable to transactivate the genes, transactivation-
independent functions were still working.
Regulation of p53 protein
The  p53  protein  is  expressed  at  very  low  levels  in  the  nucleus  of  normal  cells  but  in  the
presence of a variety of stress signals, the level of p53 becomes elevated. The amount and
subcellular localization of p53 protein are regulated mainly by the human homologue of the
murine double minute gene 2 (MDM2) which functions as an ubiquitin E3 ligase (for a
review, see Lacroix et al. 2006; Hollstein and Hainaut, 2010). MDM2 binds to the N-terminal
region of the p53 protein, ubiquitinates the C-terminal lysines of p53 which reveals the
NES.  This  leads  to  the  export  of  p53  from  nucleus  to  cytoplasm  where  it  is  degraded
(Lacroix et al. 2006; Hollstein and Hainaut, 2010). After DNA damage, MDM2 becomes
destabilized and degraded and p53 protein is phosphorylated and acetylated (Hock and
Vousden, 2010). This leads to diminished MDM2-p53 binding and thus p53 levels are
elevated and p53 becomes activated. Without an activating signal (e.g. DNA damage) wt
p53 transactivates the MDM2 gene increasing the amount of the MDM2 protein and thus
creating a reserve of MDM2 protein in the cell i.e. through this feedback loop p53 is able to
control its own degradation. After the stimulus of DNA damage has abated, re-stabilized
MDM2 can inactivate p53 (Lacroix et al. 2006; Hollstein and Hainaut, 2010). This
mechanism assures that after the DNA damage has been repaired, the level of p53 declines
and there are no further reactions in the cell, e.g. apoptosisis is not triggered. MDM4 (also
called MDMX) regulates p53 in co-operation with MDM2. It is homologous to MDM2 but it
does not possess E3 ligase activity. Thus, it is not able to ubiquitinate p53 but it can enhance
MDM2  mediated  ubiquitination  and  degradation.  In  addition,  MDM4  may  inhibit
transcriptional activity of p53 (for a review, see Wade and Wahl, 2009; Mancini et al. 2010;
Hock and Vousden, 2010).
MDM2 and MDM4 are not the only p53 regulators in cells. In addition to these proteins,
there are the E3 ligases PIRH2 (p53-Induced protein with a RING-H2 domain) and COP1
(Constitutively Photomorphogenic 1), that ubiquitinate p53 and repress its functions. These
proteins also participate in the auto-regulatory feedback loop that controls p53 function.
ARF-BP1 (ARF-Binding Protein 1) E3 ligase binds p53 protein also preventing its functions.
There are also several other proteins, e.g. CHIP (C-terminus  of  hsc70-interacting protein)
and HAUSP (deubiquitination enzyme Herpesvirus-associated ubiquitin specific protease)
which can regulate the function and degradation of p53 (Lacroix et al. 2006; Hollstein and
Hainaut, 2010). The significance of these different degradation and regulation pathways of
p53 is to link p53 with different signaling pathways which are induced by different stresses,
and to ensure proper degradation of p53 protein.
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2.4.4 Post-translational modifications of p53 protein
In addition to MDM2-mediated ubiquitination which is the main controller of p53 level in
cells, p53 protein can be post-translationally modified at many amino acid residues (for a
review, see Bode and Dong, 2004; Lavin and Gueven, 2006; Meek and Anderson, 2009;
figure 9; table 5). The different types of modifications include phosphorylation and
acetylation which often activate p53, whereas ubiquitination is more often involved in its
degradation (table 6; Hollstein and Hainaut, 2010). It has been noted that different stresses
e.g. UV-light, carcinogens and oncogene activation, cause different p53 post-translational
modifications leading to stress-specific and controlled responses in the p53-pathway (Bode
and Dong, 2004; Lavin and Gueven, 2006; Waning et al. 2010). However, Blattner et al.
(1999) used a transfected murine cell line to reveal that p53 could be stabilized and
activated without post-translational modifications after DNA damage. Thompson et al.
(2004) also showed in human colon cancer cells that after treatment with the MDM2
antagonist nutlin-3, which displaces p53 from the MDM2 binding, that the p53 protein was
activated without phosphorylation. It is not known whether or not this is the case in vivo.
Even though there is information about the post-translational modifications of p53 protein,
it  must  be  remembered that  most  studies  have been conducted only  in  vitro  with  specific
cell lines and with various constructs which may not reveal the ultimate truth about the
functions of these proteins in vivo (Goldstein et al. 2011). Thus, it is important to study the
effects of modifications separately in human cell lines and to extent these studies to the in
vivo level.
Figure 9. Known post-translational modifications of full-length human p53. Amino acids: serine
(S), lysine (K), threonine (T), arginine (R). Modifications: phosphorylation (P), acetylation (Ac),
neddylation (N), methylation (M), sumoylation (S) and glycosylation (G). (Modified from Lavin
and Gueven, 2006; Meek and Anderson, 2009).
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Phosphorylation
Phosphorylation of p53 has been shown to lead p53 protein stabilization and activation but
also to its degradation. p53 can be phosphorylated at many serine and threonine residues
both in the N-terminal and C-terminal regions (for reviews, see Bode and Dong, 2004,
Matsumoto et al. 2006; Lavin and Gueven, 2006). There are many different kinases, e.g. p38
kinase, JNK, CHK1/2 that can phosphorylate different amino acids. In addition, the same
amino acid can be phosphorylated by several different kinases (Bode and Dong, 2004; Lavin
and Gueven, 2006). p53 phosphorylation at serines (S) 15 and 20, and threonine (T) 18 have
been shown to repress binding of MDM2 to p53 preventing p53 degradation. They have
also  been  shown  to  increase  the  expression  of  pro-apoptotic  genes  in  human  glioma  cells
(Amano et al. 2009). In addition, phosphorylations at S15, S20, S33, S37, S46, T55 and T18 of
p53 have been linked to protein stabilization and transactivation of p53 through an
interaction with p300/CBP (for reviews, see Bode and Dong 2004; Meek and Anderson,
2009). In addition in MCF-7 cells, phosphorylation at S46 is associated with apoptosis (Oda
et al. 2000, Yoshida et al. 2006). The role of S46 phosphorylation in DNA-damage induced
apoptosis has also been studied by Feng et al. (2006) who reported that a mutation of S46 to
alanine reduced the p53-dependent apoptosis in HUPKI-mice derived cells. The genome-
wide DNA-binding and expression analysis conducted by Smeenk et al. (2011) revealed
also that etoposide treatment led to S46 phosphorylation of p53 protein which was then
able to bind to the target genes involved in apoptosis.
With respect to the C-terminal serine modifications, phosphorylation at S215 was shown to
prevent DNA-binding and transactivation activity of p53 (Liu et al. 2004) while S376 and
S378 are constitutively phosphorylated and involved in p53 degradation (Lacroix et al.
2006). Phosphorylation at S315 has been shown to have an anti-apoptotic function by
inhibiting the binding of Bcl-2/Bcl-XL to p53 (Nantajit et al. 2010). However, in vivo studies
on S312 of mouse p53 (equivalent to human S315) have shown that phosphorylation of this
site is not necessary for the function of p53 protein (Lee et al. 2011). S392 phosphorylation,
is a well known way to achieve p53 stabilization (Sakaguchi et al. 1997), and to trigger
sequence-specific DNA-binding and transcriptional activity (Keller et al. 2001). A recent
study has also shown that S392 can be phosphorylated under normal, unstimulated
conditions (Cox and Meek, 2010). However, the level is significantly increased in the
presence of several harmful stimuli (UV, etoposide, IR) leading to p53 stabilization.
Phosphorylation of threonine residues has similar effects on p53 protein as phosphorylation
at its serine residues. T81 phosphorylation is postulated to be associated with p53
stabilization; T377 and T378 phosphorylations affect the extent of lysine 373 (K373) and
K382 acetylation; T55 and T155 phosphorylation are known to enhance the degradation of
p53 (Lacroix et al. 2006).
Acetylation
p53 acetylation has three recognized functions: 1) to prevent ubiquitination, 2) to inhibit the
formation of MDM2 repressive complexes on target gene promoters, and 3) to recruit
cofactors for the promoter-specific activation of p53 transcriptional activity (for a review,
see Dai and Gu, 2010). Acetylation of many C-terminal lysine (K) residues (370, 372, 373,
381, 382 and 386) via p300/CBP contributes to p53 stabilization by impairing MDM2-
ubiquitination (Li et al. 2002; Yoshida and Miki, 2010). K320 is in the oligomerization
domain region and its acetylation induces cell survival through p53-dependent activation
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of the genes involved in cell cycle arrest (Dai and Gu, 2010). The K120 and K164 residues
are in the DNA binding domain and acetylation of K120 is induced by DNA damage. It has
been shown that this modification leads to binding of p53 to pro-apoptotic promoters, but
not to the cell cycle promoters. Mutations where lysine is substituted with other amino
acids  at  this  site  lead  to  a  failure  to  induce  apoptosis  and  this  explains  why  this  site  is  a
target for many of the mutations encountered during tumor development (Reviewed by
Meek and Anderson, 2009; Dai and Gu, 2010).
Other modifictions
In addition to phosphorylation and acetylation, p53 can be also sumoylated, neddylated,
methylated, ADP-ribosylated and glucosylated. SUMO E3 ligases (small ubiquitin-related
modifiers), which are mainly from PIAS-family (protein inhibitor of activated STAT)
sumoylate the K386 residue of p53 protein. The effect of sumoylation is not completely clear
but it has been speculated that it can affect the function of p53 protein by altering its sub-
cellular localization or antagonizing other modifications. There are also conflicting reports
about the effects of sumoylation on transcriptional activity of p53 (for reviews, see Lacroix
et al. 2006; Olsson et al. 2007; Hock and Vousden, 2010). According to Bischof and co-
workers (2006), sumoylation is able to increase the transcriptional activity of p53. In
contrast, Wu and Chiang (2009) have reported that sumoylation can also suppress p53
transcription leading to inhibition of activation of target genes. NEDD8 (neuronal precursor
cell-expressed developmentally down-regulated protein 8), a small ubiquitin-ligase, can
bind to several lysines within the C-terminus of p53. Neddylation can be perfomed by
MDM2 at K370, K372, K373 residues, and by FBXO11 at K320, K321 residues, leading to
reduced transcriptional activity of p53 (Xirodimas et al. 2004; for review, see Hock and
Vousden, 2010).
Methylation of arginine (R) 333, 335 and 337 residues in the oligomerization domain affects
the target gene specificity of the transcription function of p53. Lysine methylation can either
activate or repress p53 functions; this being apparently dependent upon the localization of
the modification and the number of attached methyl groups (Dai and Gu, 2010). ADP-
ribosylation is involved in the regulation of several cellular functions. The main responsible
enzyme is poly(ADP-ribose) polymerase 1 (PARP-1) which is activated by DNA strand
breaks, thus associating p53 with the protein activities involved in DNA replication, DNA
repair and checkpoint control (Lacroix et al. 2006). Glycosylation (addition of O-GlcNAc)
stabilizes p53 protein (for a review, see Özcan et al. 2010). For example, S149 glycosylation
with O-GlcNAc interferes with phosphorylation at T155 and this leads to detachment of
p53-MDM2 binding and thus stabilization of p53 protein. However, it has been proposed
that there are probably other residues that become O-GlcNAc modified, leading to
inhibition of intramolecular interactions, because the S149A mutation does not decrease O-
GlcNAc modification of p53 (Özcan et al. 2010).
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Table 5. p53  modifications  and  their  effects  on  the  function  of  the  protein  (Bode  and  Dong,
2004; Lacroix et al. 2006; Matsumoto et al. 2006; Olsson et al. 2007; Kruse and Gu, 2009;
Meek  and  Anderson,  2009;  Dai  and  Gu,  2010;  Hock  and  Vousden,  2010;  Yoshida  and  Miki,
2010; Özcan et al. 2010; see also text for references).
Modification and
the binding group
Amino acids
known to be
modified
Function / effect
Phosphorylation Serine 6, 9 mesoderm development, metastatic progression, partially
unknown functions
Serine 15 repression of MDM2-p53 binding, stabilization, transactivation
function, apoptosis
Serine 20 repression of MDM2-p53 binding, stabilization, transactivation
function, apoptosis
Serine 33, 37 stabilization, transactivation function
Serine 46 apoptosis, stabilization, transactivation function
Serine 215 prevention of DNA binding, inhibit transactivation activity
Serine 313 unknown
Serine 314 unknown
Serine 315 oligomerization, DNA binding, anti-apoptotic function
Serine 366 unknown
Serine 376, 378 p53 degradation
Serine 392 stabilization, oligomerization, DNA binding, transcriptional activity
Threonine 18 repression of MDM2-p53 binding, stabilization, transactivation
function
Threonine 55 enhancement of p53 degradation
Threonine 81 stabilization
Threonine 155 enhancement p53 degradation
Threonine 377, 378 affect K373 and K382 acetylation
Acetylation Lysine 120 binding of pro-apoptotic promoters (PUMA, Bax)
Lysine 164 p53 target gene activation
Lysine 305 unknown
Lysine 320 transcriptional acitivity, growth arrest, cell survival
Lysine 370, 372,
373, 381, 382, 386
impairs MDM2 ubiquitination of p53
Sumoylation
(SUMO-protein)
Lysine 386 alterations in sub-cellular localization,
antagonizes other modifications,
increase or suppression of transcriptional activity
Neddylation
(NEDD8-protein)
Lysine 320, 321,
370, 372, 373
reduced p53 transcriptional activity
Methylation Arginine 333, 335,
337
influences target gene specificity of p53
Lysine 370, 372,
373, 382
activation or repression
ADP-ribosylation contribution to DNA replication, DNA repair, checkpoint control,
nuclear accumulation
Continues…
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Table 5. continued
Glycosylation Serine 149 stabilization,
interferes the phosphorylation of T155
Other residues stabilization
Mono- or Poly-ubiquitination
(Ubiquitin-protein)
K320, K370,
K372, K373,
K381, K382,
K386
cytoplasmic localization, degradation, cell cycle arrest
Olsson and coworkers (2007) have summarized the situation by stating that DNA damage
has been reported to lead to several different post-translational modifications of p53:
phosphorylation at serines 6, 9, 15, 33, 37, 46, 315, 392; phosphorylation at threonines 18 and
81; acetylation at lysine 120; methylation at lysines 370 and 372; and sumoylation at lysine
386. Different stress stimuli cause different modifications at different amino acid residues
which have the capability to cause specific p53-responses in cell, according to the level of
damage in cell. In addition, modifications of other components of the p53 pathway (e.g.
MDM2) contribute to responses complicating further clarification of the p53 pathway-
related responses.
2.4.5 Functions of p53 protein
Activation of the p53 protein through different modifications can lead to several responses
in the cell. By acting as a transcription factor, p53 may induce or inhibit the transcription of
several genes. In addition, p53 also has transcription-independent functions. The principal
responses of p53 are cell cycle arrest and apoptosis. p53 is involved also in several other
cellular responses, e.g. DNA repair, senescence, survival and autophagy. These are
essential if one considers its functions as a tumor suppressor and in fetal development as a
suppressor of teratogenesis (figure 10). It is still largely unknown how different types of
cellular stress are able to trigger different kinds of p53-induced cellular responses.
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Figure 10. p53  pathway  after  different  types  of  cellular  stress.(Modified  from  Guimaraes  and
Hainaut, 2002; Hussain and Harris, 2006; Högberg et al. 2009).
Cell cycle arrest
The ultimate goal of p53-induced cell cycle arrest is thought to be to provide time to allow
repair  of  damaged  DNA  in  cells.  Otherwise,  the  damage  can  result  in  the  presence  of
mutations in daughter cells after DNA replication and thus contribute to tumor formation.
Four  steps  can  be  differentiated  in  the  cell  cycle:  gap  1  protein  synthesis  (G1),  DNA
synthesis  (S),  gap 2  protein  synthesis  (G2)  and mitosis  (M).  p53 protein  is  involved in  G1
and G2 cell cycle arrest through different proteins (figure 11). The p21WAF1/CIP1 protein which
is a cyclin-dependent kinase (CDK) inhibitor, is responsible for G1 cell-cycle arrest (El-
Deiry et al. 1993; Harper et al. 1993). It is known that p21 inhibits cell proliferation by
interfering with E-Cdk2-mediated phosphorylation of Rb (Harper et al. 1993; Stewart and
Pietenpol, 2001; Wang and El-Deiry, 2007). The importance of p21 is illustrated in p21
knockout mice where embryonic fibroblasts do not become arrested in G1 after suffering
DNA damage (Deng et al. 1995). Other p53 transcriptional targets, in addition to p21, that
contribute to G2 cell  cycle arrest are GADD45 (growth arrest and DNA damage inducible
gene) and 14-3-3 which inhibit the activation Cdc2/CyclinB1 (Hermeking et al. 1997; Zhan
et al. 1998; Taylor and Stark, 2001).
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Figure 11 Main pathways for the participation of p53 in cell cycle regulation (Modified from
Vähäkangas, 2003b; Wang and El-Deiry, 2007).
Apoptosis
Apoptosis is triggered in those cells where carcinogenic and genotoxic substances have
evoked  overwhelming  damage,  e.g.  DNA-damage.  p53  is  involved  in  both  the  death
receptor and the mitochondrial mediated (extrinsic and intrinsic) apoptotic routes. In the
death receptor-mediated route, nuclear p53 protein induces the expression of death
receptors, and in the mitochondrial-mediated route, it induces the expression of Bcl-2
family proteins, e.g. PUMA, Noxa, Bax (for reviews, see e.g. Haupt et al. 2003, Hofseth et al.
2004; Vousden and Lane, 2007). Originally p53 protein was thought to act in the nucleus
and the only reason for its transfer to cytoplasm was to achieve its degradation. However,
today  there  is  clear  evidence  showing  that  cytoplasmic  p53  plays  an  important  role  in
apoptosis (Green and Kroemer, 2009). In cytoplasm, particularly in the outer mitochondrial
membrane, p53 can interact with both the pro-apoptotic and anti-apoptotic proteins (for a
review, see Green and Kroemer, 2009; Speidel, 2010). By interacting with different proteins,
p53 can either repress or induce the function of these proteins, ultimately leading to
mitochondrial outer membrane permeabilization.
When  p53  is  present  in  the  cytoplasm,  it  is  transferred  to  mitochondrial  outer  membrane
(Marchenko and Moll, 2007) where it can bind to anti-apoptotic Bcl-2 or Bcl-XL proteins.
The  significance  of  this  binding  is  contradictory.  It  has  been  postulated  (for  review,  see
Speidel, 2010 and references therein) that by binding to these proteins, p53 can prevent
their anti-apoptotic function promoting thus apoptosis. It has been also proposed that
binding of p53 to Bcl-2 or Bcl-XL can inhibit the apoptotic function of p53, thus preventing
apoptosis  (Chipuk et  al.  2005).  The release  of  p53 from Bcl-2  or  Bcl-XL by PUMA leads  to
p53 activation and induction of  apoptosis  (Chipuk et  al.  2005).  However,  it  is  known that
p53 is able to interact with pro-apoptotic Bax (Chipuk et al. 2004) and Bak (Pietsch et al.
2008). The interaction leads to the oligomerization of Bax and Bak proteins which in turn
triggers the formation of pores in the mitochondrial membrane. The formation and opening
of these pores promote the release of cytochrome c and other apoptotic activators  from
mitochondria (Chipuk et al., 2004; Mihara et al., 2003; Tomita et al., 2006) leading ultimately
to activation of the caspase cascade and finally to apoptosis. In summary, p53 protein is
31
involved in apoptosis at both the transcriptional and non-transcriptional levels indicating
that p53-mediated apoptosis is a result of multiple pro-apoptotic signals (Speidel, 2010).
Endoplasmic reticulum stress
The endoplasmic reticulum (ER) has an important function in protein synthesis, folding
and trafficking, calcium homeostasis, and lipid and steroid synthesis. Secreted proteins,
plasma membrane and organelle proteins are all synthesized in ER and thus disruption of
ER homeostasis by accumulation of misfolded or unfolded proteins can lead to
endoplasmic  reticulum  (ER)  stress  which  interferes  with  cellular  function  possibly
triggering cell death. This kind of pathology is involved in many different diseases
(Schröder and Kaufman, 2005; Engin and Hotamisligil, 2010). The unfolded protein
response (UPR) detects the misfolded proteins and attempts to maintain homeostasis and
normal protein levels in the ER (Rasheva and Domingos, 2009). p53 protein and particularly
its shorter isoform p53/47 is known to be involved in the UPR by promoting G2/M cell cycle
arrest (Bourougaa et al. 2010; Olivares-Illana and Fåhraeus, 2010). Protein kinase RNA
(PKR)-like kinase (PERK) is a transmembrane protein which has the ability to sense the ER
stress within the cell (Rasheva and Domingos, 2009). Bourougaa et al. (2010) have shown
that ER-stress evokes PERK–dependent induction of p53/47 mRNA translation and also the
homo-oligomerization of the p53/47 protein. Stress-induced p53/47 activation leads to 14-3-
3 activation and ultimately to G2/M arrest. This mechanism diminishes protein synthesis
and cap-dependent protein translation becomes suppressed.
Other properties
p53 has been shown to participate in several DNA repair process, e.g. nucleotide excision
repair, base-excision repair and mismatch repair. p53 may regulate the repair in a
transcription-dependent  manner  by inducing the  expression of  proteins  involved in  DNA
repair, or in a transcription-independent way by interacting with the repair proteins (for
review, Sengupta and Harris, 2005; Gatz and Wiesmüller, 2006; Högberg et al. 2009).
Cellular senescence has been described as an arrest of cell cycle after a fixed number of cell
doublings (Jackson et al. 2011). Permanent cell cycle arrest can be regarded as a tumor
suppressive mechanism where p53 protein is believed to be involved (Campisi, 2001;
Collado and Serrano, 2010). In addition to apoptosis, p53 can regulate autophagy in a dual
manner (for review, see Maiuri et al. 2010). Thus, though nuclear p53 transactivates pro-
autophagic genes, it seems that cytoplasmic p53 can repress autophagy via mechanisms
which are still poorly understood (Maiuri et al. 2010). Finally, p53 is involved in
metabolism (for review, see Vousden, 2009). Starvation has been shown to induce p53
protein, thus preventing undesirable cell proliferation. p53 also inhibits glycolysis and
promotes oxidative phosphorylation, ultimately preventing tumor growth (Vousden, 2009).
Thus, p53 protein is a frontline player in the survival functions of the cell (Guimaraes and
Hainaut, 2002; Högberg et al. 2009). Even though p53 responds to endogenous cellular
stress, its main function seems to be to protect the cell from exogenous, harmful effects,
including carcinogenesis (Hainaut and Vähäkangas, 1997). Today, humans are exposed to
plethora chemicals through environment, food, and cosmetics etc. that are known to be
carcinogenic in humans. It is apparent that different chemicals evoke different kinds of
responses from p53 (Guimaraes and Hainaut, 2002; Hussain and Harris, 2006; Högberg et
al. 2009). These responses may also vary according to the tissue. Clarification of the
responses of p53 to different kinds of exposures in different cell models, e.g. cell lines
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derived  from  human  breast,  lung  and  liver,  is  one  way  to  provide  information  about  the
tissue specific responses to the exposure.
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3 Aims
Breast  cancer  is  the  most  frequent  type of  cancer  in  women and there  are  indications  that
tobacco smoke, which is known to contain many carcinogenic PAHs, may increase the risk
of this disease. The ultimate aim of the research program is to reveal mechanisms in BP-
induced carcinogenic effects in breast tissue. BP has to be metabolized to mutagenic and
carcinogenic products before it exerts any effects in the cell. One indicator of BP-
metabolism  is  the  formation  of  BPDE-DNA  adducts,  which  means  that  BP  has  been
metabolized to its active diol-epoxide form. It is known that p53 protein is induced after
BP-treatment  e.g  in.  MCF-7  cells.  In  order  to  be  activated,  p53  protein  has  to  be  post-
translationally modified in many amino acids and these modifications (phosphorylation,
acetylation etc.) are linked to many important functions of the cell, e.g. in apoptosis. In this
study it was intended to clarify the effects of BP on p53-related cellular responses in vitro in
human breast cancer cell lines. In addition, this study aimed to characterize several cell
lines because more than one cell line is necessary if one wishes to determine whether BP-
induced cellular responses are breast tissue specific or cell line specific.
The specific objectives of this study were:
 To characterize the TP53 status and BP metabolism in five human breast cancer cell
lines and to compare responses after BP treatment in cells with wild type or mutated
TP53
 To reveal the role of p53 phosphorylation in BP-induced cell death
 To elucidate the effects of BP on p53 and related proteins in breast cancer cell lines
with wild type p53
 To  confirm  the  role  of  p53  in  BP-induced  cellular  responses  by  using  its  inhibition
(PFT- and p53-siRNA)
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4 Materials and Methods
4.1 CELL LINES
4.1.1 Breast cancer cell lines (I-IV)
All cell lines were established in 1970’s from human breast cancer specimens (table 6).
MCF-7 adenocarcinoma cell line was isolated at the beginning of 1970’s from a 69 year old
woman. Cells were isolated from pleural effusion. The ZR-75-1 ductal carcinoma cell line
was isolated in the late 1970’s from a 63 years old woman and it is derived from metastatic
ascites. MDA-MB-231 adenocarcinoma cell line was isolated in the mid 1970’s from a 51
year old woman after pleural effusion. MDA-MB-468 adenocarcinoma cell line was isolated
in the late 1970’s from pleural effusion from a 51 year old woman. The T47-D ductal
carcinoma cell line was isolated in the late 1970’s from pleural effusion taken from a 54 year
old woman.
Table 6. Characteristics of breast cancer cell lines
Cell line Original cancer First described
MCF-7 adenoca Soule et al. 1973
ZR-75-1 ductal ca Engel et al. 1978
MDA-MB-231 adenoca Cailleau et al. 1974
MDA-MB-468 adenoca Cailleau et al. 1978
T47-D ductal ca Keydar et al. 1979
ca = carcinoma
4.1.2 Other cell lines (I)
The A549 cell line was established in 1972 by Giard and co-workers (1973) through explant
culture of lung carcinoma tissue from a 58-year-old male. These cells have a wild type TP53
gene (Lehman et al. 1991; Rämet et al. 1995) and a capability to metabolize BP resulting in
BPDE-DNA adducts, although much less than the MCF-7 cells (Rämet et al. 1995).
4.1.3 Cell culture and treatments (I-IV)
Details for the cell culture media for each cell line are shown in table 7 and in original
publications  (I-IV).  All  cell  lines  were  cultured  at  37  °C  in  a  cell  culture  incubator  with  a
humidified atmosphere containing 95 % air and 5 % CO2.
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Table 7. The most important ingredients of the cell media.
Cell line
MCF-7 ZR-75-1 MDA-MB-231 MDA-MB-468 T47-D A549
Medium DMEM RPMI 1640 DMEM DMEM RPMI 1640 DMEM
Glucose 4.5 g/l 2 g/l 4.5 g/l 4.5 g/l 2 g/l 4.5 g/l
L-glutamine 0.6 g/l 0.3 g/l 0.6 g/l 0.6 g/l 0.3 g/l 0.6 g/l
FBS 9 % 9 % 9 % 9 % 9 % 9 %
Gentamycin 10 μg/ml 10 μg/ml 10 μg/ml 10 μg/ml 10 μg/ml 10 μg/ml
Insulin 4 μg/ml - - - 8 μg/ml -
HEPES - 10 mM - - 10 mM -
Na-pyruvate - 1 mM - - 1 mM -
Estradiol 10 nM - - - - -
Cells were detached with 0.05% trypsin–0.02% EDTA in order to subculture the cells for
experiments. After subculturing (on 48-well plate, 6-well plate or Ø 9 cm cell culture dish),
the cells were cultured for 24-72 hours in a cell culture incubator before the treatments were
started. Cells were treated with different (1, 5, 10, 20 and 40 μM) concentrations of
benzo(a)pyrene (BP) (Sigma) which was dissolved in dimethyl sulfoxide (DMSO, Sigma).
Control cells were treated with 0.1 or 0.2 % DMSO. Cells were exposed to BP for 24, 48 or 72
hours. The methodological techniques used in this study are presented in Table 8.
Table 8. Methodologies used in the study.
Parameter Method Reference Publication
Protein analysis -Immunoblotting Serpi et al. 1999;
Turpeinen et al. 2002
I-IV
Cell viability -Propidium iodide (PI) and digitonin Sarafian et al. 1994;
Loikkanen et al. 1998,
2003a, 2003b
I-IV
-MTT test Penttinen et al. 2007 II
-PI exclusion test Penttinen et al. 2007 II
Apoptosis -Caspase-3-like protease activity Loikkanen et al. 2003a I
-Internucleosomal DNA fragmentation Herrmann et al. 1994;
Loikkanen et al. 2003a
I
-DNA content analysis Penttinen et al. 2006 II
-Cytochrome c visualization by confocal
microscopy
Hietakangas et al. 2003 II
BPDE-DNA adducts -Synchronous fluorescence
spectrophotometry
Vähäkangas et al. 1985 I, III
Reactive oxygen
species (ROS)
-2’,7’-dichloro-dihydrofluorescein
diacetate (H2DCFDA)
Sarafian et al. 1994;
Loikkanen et al. 2003b
II
TP53 mutation
analysis
-PCR and sequencing Lehman et al. 1991;
Vähäkangas et al. 1992
III
p53 inhibition - Pifithrin- treatment - IV
- RNA interference (RNAi) - IV
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4.2 ANALYSIS OF TP53 MUTATIONS
4.2.1 Polymerase chain reaction (PCR) (III)
TP53 exons 5-8 were amplified for sequencing by PCR. DNA was isolated from different
cell lines using phenol-chloroform extraction and the ethanol precipitation method or using
NucleoSpin® Tissue XS (Macherey-Nagel GmbH & Co. KG, Germany) genomic DNA
isolation kit. Specific primers of human TP53 exons were used to amplify TP53 gene exons
5-8. The exact details of the PCR method and the primers are described in publication III.
4.2.2 Sequencing (III)
After  purification  with  QIAquick  Gel  Extraction  Kit  (QIAGEN),  PCR  products  were
sequenced using MegaBACE 750 (Amersham) DNA Analysis System (fluorescence based
system utilizing capillary electrophoresis). DYEnamic ET Dye Terminator Chemistry Cycle
Sequencing System with Thermo Sequenase II DNA Polymerase (Amersham Biosciences)
was used.
The obtained sequences were compared to individual exon sequences from the IARC TP53
database (http://www-p53.iarc.fr/TP53sequence_NC_000017-9.html) using the Nucleotide
BLAST alignment program (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
4.3 ANALYSIS OF BP-TREATMENT DERIVED SPECIES
4.3.1 Benzo(a)pyrene-diolepoxide-DNA adducts (I, III)
Synchronous fluorescence spectrophotometry was originally described by Lloyd (1971) for
analytical chemistry and applied by Vähäkangas and co-workers (1985) to detect BPDE-
DNA adducts. Briefly, DNA was isolated from different cell samples using phenol-
chloroform extraction and ethanol precipitation. Isolated DNA was hydrolyzed by treating
the samples in 0.1 M HCl at 95C for 3 hours. Thereafter, the samples were scanned using
the 34 nm wavelength difference between emission and excitation. One fluorescence unit is
equal to approximately 1.1 fmol BPDE/μg DNA. By scanning excitation and emission
synchronously with a 34 nm wavelength difference, fewer peaks occur because a signal is
detected only when the wavelength difference matches the interval between of one
absorption and one emission band (Vähäkangas et al. 1985).
4.3.2 Reactive oxygen species (ROS) (II)
Production of ROS was analyzed with a method where cell-permeant 2’,7’-dichloro-
dihydrofluorescein diacetate (H2DCFDA) is loaded in cells. During the loading, the non-
fluorescent 2’,7’- dichlorodihydrofluorescein (H2DCF) is formed in cells. Water-soluble
H2DCF  remains  inside  the  cells  where  it  is  oxidized  in  the  presence  of  ROS  to  the  highly
fluorescent compound, 2’,7’-dichloro-fluorescein (DCF) (Sarafian et al. 1994; Loikkanen et
al. 2003b).
4.4 CELL VIABILITY
4.4.1 Propidium iodide – digitonin (I, III, IV)
The propidium iodide (PI) – digitonin cell viability measurement is based on the method
described by Sarafian and co-workers (1994). PI is excluded from viable cells but dead or
dying cells are permeable to PI. Binding of PI to nucleic acids increases its fluorescence up
to 20-30 fold. Treatment with digitonin damages the cell wall, enabling PI binding to
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nucleic acids present in all cells (living and dead). This reflects the total cell amount in the
experiments and makes it possible to calculate percentual cell viability.
4.4.2 MTT test (II)
In MTT test exogenously administered MTT solution [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide] is converted to the colored formazan by the functional
mitochondria within cells (Mosmann, 1983). This reflects the amount of viable cells. The
formation of formazan is measured as absorbance in a spectrophotometer. Briefly, the cell
suspension and MTT-solution (Sigma-Aldrich, USA) were mixed and incubated and then
sodium dodecyl sulfate (SDS) buffer was added. Incubation was continued overnight and
absorbance was measured in a microplate reader (Victor3, PerkinElmer, Finland) and
analyzed with the WorkOut software version 1.5 (Dazdaq Ltd., Brighton, UK). The
proportion of viable cells in exposed samples was compared to a control sample (Penttinen
et al. 2007).
4.4.3 PI exclusion test (II)
Necrotic and late apoptotic cells with low cell membrane potential are permeable to PI. The
total number of dead cells can be detected by flow cytometry as described in Penttinen et al.
2007. Briefly, a fresh cell suspension was centrifuged and cells were resuspended into PBS
and PI (Sigma-Aldrich, USA) was added. Samples were incubated before flow cytometric
analysis (CyAn ADP, Beckman Coulter, USA). A total of 10,000 cells per sample was
analyzed by Summit software version 4.3.
4.5 APOPTOSIS
4.5.1 Caspase-3-like protease activity (I)
The fluorescent caspase-3 substrate, acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin
(Ac-DEVD-AMC), was used to measure caspase-3-like protease activity. According to the
manufacturer (Calbiochem, Darmstadt, Germany), Ac-DEVD-AMC is recognized also by
caspases 6, 7, 8 and 10 (caspase-3-like protease activity). Activated caspase cleaves AMC
from the substrate, resulting in increased fluorescence reflecting the caspase activity.
After the exposure, the medium was removed and cells were scraped in ice cold PBS and
centrifuged. PBS was removed and cell pellets were stored at -70 °C until measurements.
Cells were thawed on ice and suspended into lysis buffer (10 mM Tris; 130 mM NaCl; 1 %
Triton X-100; 10 mM NaH2PO4; 10 mM Na2HPO4 pH7.5). Samples were centrifuged after the
incubation and subsequently the supernatant was collected and kept on ice. Protein
concentrations were measured with the Bradford method using protein assay reagent (Bio-
Rad Laboratories). Caspase-3-like activity was measured from samples with Ac-DEVD-
AMC  in  assay  the  buffer  (20  mM  Hepes,  pH  7.5,  10  %  glycerol,  2  mM  DTT)  (positive
samples) and from samples in the assay buffer (negative samples) after incubation at 37 °C.
Measurement was conducted with the Victor™ Plate Reader (PerkinElmer, Finland) at an
excitation wavelength of 355 nm and an emission wavelength of 460 nm. Caspase-3-like
activity  was  quantified  against  AMC  standards  and  is  presented  as  pmol  of  AMC
released/min per mg of protein.
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Since  BP  is  fluorogenic,  it  was  important  to  correct  the  results  for  any  interference  by  BP
fluorescence. Without such a correction, very high biased values for caspase-activity have
been reported (Yoshii et al. 2001; Ko et al. 2004; Kim et al. 2005). Corrected activity was
calculated by subtracting the activity of negative samples (without substrate) from positive
samples (with substrate).
4.5.2 Internucleosomal DNA fragmentation (I)
During apoptosis, chromosomal DNA becomes degraded by nucleases into 180 bp
fragments (Robertson and Orrenius, 2002) which can be detected using agarose gel
electrophoresis  and ethidium bromide (EtBr)  staining.  Isolation of  fragmented DNA from
cells is based on the method described by Herrmann and co-workers (1994). After exposure,
the cells were scraped in medium and centrifuged. The cells were washed with PBS and
treated twice with a lysis buffer (50 mM Tris-HCl; 20 mM EDTA; 1 % Nonidet P-40, pH 7.5).
After each lysis step, samples were centrifuged. RNA and proteins were degraded with
RNase A and proteinase K, respectively. Finally, DNA was precipitated with ethanol,
dissolved in TE-buffer (10 mM Tris-HCl; 1 mM EDTA, pH 8.0) and loaded on agarose gel (1
%) for electrophoresis. After electrophoresis, DNA was visualized with EtBr staining. DNA
isolated from mouse hypothalamic GT1-7 neuronal cells grown in the absence of serum was
used as a positive control (Loikkanen et al. 2003a).
4.5.3 DNA content analysis by flow cytometry (II)
DNA content was analyzed by PI staining of permeabilized cells, where apoptotic cells can
be identified as the cells containing fragmented DNA (sub-G1 fraction) (Darzynkiewicz et
al. 1992). This method also provides information about the cell cycle of the non-apoptotic
cells. In brief, cells were fixed in ice cold ethanol and stored until staining with PI.
Subsequently, the cells were pelleted and incubated with RNase A (Ribonuclease A, Sigma-
Aldrich,  USA).  PI  (Sigma-Aldrich,  USA)  was  added  and  the  incubation  was  continued
before flow cytometric analysis (CyAn ADP, Beckman Coulter, USA, em. 613 ± 20 nm). A
total of 10,000 cells per sample were analyzed by Summit software version 4.3 (Penttinen et
al. 2006).
4.5.4 Cytochrome c visualization by confocal microscopy (II)
Cytochrome c release was visualized by confocal microscopy using an immunofluorescent
technique with the slight modifications described by Hietakangas and coworkers (2003).
Briefly,  the  cells  on glass  coverslips  were  fixed after  which they were  permeabilized with
Triton X-100 in PBS. The samples were incubated first with blocking solution, then with
anti-cytochrome c (Pharmingen, San Diego, CA, USA), and finally with the Alexa Fluor 488
goat anti-mouse IgG (Molecular Probes, Eugene, Oregon, USA) antibody. Finally, samples
were incubated with PI (Molecular Probes) in order to stain their nuclei. Samples were
mounted on the objective slides with Vectashield (Vector Laboratories, Burlingame, CA,
USA) and sealed. The slides were protected from light and stored. Visualization was done
with the UltraView confocal image system (Perkin Elmer, UK) attached to a Nikon Eclipse
TE300 microscope (Nikon Corp., Japan). Images were taken with 100x oil immersion
objective (Plan Fluor, Nikon) with a cooled digital charge-coupled device (CCD) camera
(Perkin Elmer) and further processed with Adobe Photoshop CS.
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4.6 ANALYSIS OF PROTEINS INVOLVED IN APOPTOSIS
4.6.1 Protein fractions for immunoblotting
Cytosolic and nuclear fractions (I)
After exposure, cells were washed in ice cold PBS (phosphate buffered saline) and scraped
in specific lysis buffer EMSA A (20 mM Hepes pH 7.6; 20 % glycerol; 10 mM NaCl; 1.5 mM
MgCl2;0.2 mM EDTA pH 7.6; 0.1 % Nonidet P-40; 1 mM dithiothreitol (DTT); 500 μM
phenylmethylsulfonyl fluoride (PMSF); 1.7 μg/ml aprotinin; 1 μg/ml antipain; 0.7 μg/ml
pepstatin A). The cell suspension was incubated on ice and centrifuged. Supernatants
containing cytosolic fractions were collected. Cell pellets were re-suspended in EMSA B
buffer (500 mM NaCl, otherwise the same as EMSA A). Suspension was incubated on ice
and then centrifuged. Supernatants containing the nuclear fraction were collected. The
samples were stored at -80 °C until immunoblotting analysis.
Total cell fraction (II, III, IV)
After exposure, cells were washed with ice cold PBS and scraped in EMSA B buffer (20 mM
Hepes pH 7.6; 20 % glycerol; 500 mM NaCl; 1.5 mM MgCl2; 0.2 mM EDTA pH 7.6; 0.1 % NP
40; 1 mM DTT) supplemented with protease inhibitors (Complete Mini Protease Inhibitor
cocktail tablets, Roche Diagnostics GmbH, Mannheim, Germany; used according to the
manufacturer’s instructions). The cell suspension was incubated on ice and centrifuged,
after which the supernatant containing total protein fraction was collected. The samples
were stored at -80 °C until immunoblotting analysis.
Cytosolic and mitochondrial fractions (II)
Cells  from  the  medium  and  from  the  plate  were  combined  and  collected  with
centrifugation. Thereafter, cells were fractioned according to ApoAlert® Cell Fractionation
Kit  (Clontech).  After  a  washing  step,  cells  were  suspended  in  Fractionation  buffer
(Clontech) and incubated on ice. Cells were homogenized by sucking through a 27 G
needle. Samples were centrifuged and the pellet was discarded. The remaining supernatant
was centrifuged and the supernatant obtained was the cytosolic fraction and the pellet was
the mitochondrial fraction which was suspended in Fractionation buffer (Clontech). The
samples were stored at -80 °C until immunoblotting analysis.
4.6.2 Immunoblotting (I, II, III, IV)
Before immunoblotting protein concentrations of the samples were measured by Bradford
method using protein assay reagent (Bio-Rad Laboratories, USA). Proteins were separated
electrophoretically in polyacrylamide-bisacrylamide gel containing SDS. Thereafter,
proteins were transferred to polyvinylidene difluoride membrane (PVDF). After blocking,
different proteins were recognized with specific primary antibodies (see Table 9) and finally
incubated with specific horseradish peroxidase (HRP) labeled secondary antibody (see
Table 9). Protein bands were visualized with ECL+ Plus system. The Page Ruler Plus
Prestained Protein Ladder was used to compare the molecular weights of the bands and
mouse monoclonal Anti--actin-IgG was used to detect -actin  as  a  loading  control.
Densitometric analysis was carried out using the QuantityOne® -program.
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In some case, membranes were dehybridized with stripping buffer to remove the antibody
complexes from the antigen. Thereafter, the membranes were washed and incubated in
blocking solution and reprobed as previously with primary antibody.
In order to control the purity of mitochondrial and cytosolic fractions (II), mitochondrial-
specific COX4 was immunoblotted from selected samples. The absence of COX4 in cytosolic
fraction showed that the fractionation had been successful (data not shown).
Table 9. Details of the primary antibodies used and the corresponding secondary antibodies.
Primary
antibody
Company Dilution HRP*-labeled
Secondary
antibody
Company Dilution
Anti-p53-DO-7 NovoCastra
laboratories
1:2000 Anti-mouse IgG Amersham
BioSciences
1:2000
Anti-phospho-
Ser6-p53
Cell Signaling 1:2000 Anti-rabbit IgG Cell Signaling 1:2000
Anti-phospho-
Ser9-p53
Cell Signaling 1:2000 Anti-rabbit IgG Cell Signaling 1:2000
Anti-phospho-
Ser15-p53
Cell Signaling 1:2000 Anti-mouse IgG Amersham
BioSciences
1:2000
Anti-phospho-
Ser20-p53
Cell Signaling 1:2000 Anti-rabbit IgG Cell Signaling 1:2000
Anti-phospho-
Ser37-p53
Cell Signaling 1:2000 Anti-rabbit IgG Cell Signaling 1:2000
Anti-phospho-
Ser46-p53
Cell Signaling 1:2000 Anti-rabbit IgG Cell Signaling
or
Calbiochem
1:2000
Anti-phospho-
Ser392-p53
Cell Signaling 1:2000 Anti-rabbit IgG Cell Signaling
or
Calbiochem
1:2000
Anti-caspase-7 Cell Signaling 1:2000 Anti-mouse IgG Amersham
BioSciences
1:2000
Anti-PUMA Cell Signaling 1:1000 Anti-rabbit IgG Cell Signaling
or
Calbiochem
1:1000
Anti-
Cytochrome c
Pharmingen 1:2000 Anti-mouse IgG Amersham
BioSciences
1:2000
Anti-COX4 Clontech** 1:500 Anti-mouse IgG Chemicon 1:2000
Anti-Bax SantaCruz
Biotechnology
1:2000 Anti-mouse IgG Amersham
BioSciences
1:2000
Anti--actin Sigma 1:2 million Anti-mouse IgG Amersham
BioSciences
1:2000
*HRP – horseradish peroxidase
**ApoAlert® Cell Fractionation Kit (Clontech)
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4.6.3 p53 inhibition (IV)
Pifithrin-alpha treatment
Pifithrin-alpha (p-fifty  three inhibitor, PFT-) is a chemical inhibitor of p53 protein and it
suppresses p53-mediated transactivation and apoptosis (Komarov et al. 1999).
MCF-7 and ZR-75-1 cells were subcultured either on 48-well plates (for viability
measurements)  or  on  cell  culture  dishes  (Ø  9  cm,  for  immunoblotting).  After  24  hours  of
subculturing, fresh growth medium was changed and the cells were pre-treated with 10
μM PFT- (Calbiochem, dissolved in DMSO, Sigma) for one hour before BP was added
(Sigma,  dissolved in  DMSO,  Sigma).  Cells  were  exposed to  BP for  48  hours.  Control  cells
were only exposed to 0.2 % DMSO. At 48 h, cell viability was measured with the PI-
digitonin method or total cell fractions for immunoblotting were prepared.
RNA interference
RNA interference, described for first time by Fire and coworkers (1998), is a method where
a small double stranded RNA molecule inhibits the expression of the homologous full-
length RNA. This phenomenon is mediated through small interfering RNAs (siRNA) which
are 21-23 nucleotide long RNA molecules (Fire et al. 1998).
Transfections in MCF-7 cells were carried out in 6-well plates according to the
manufacturer’s instructions (Reverse transfection, Invitrogen Life Technologies, UK).
Briefly, transfection was started by preparing the p53-siRNA or Stealth™ RNAi Negative
Control Duplex and Lipofectamine™ RNAiMAX (all from Invitrogen Life Technologies,
UK) complexes in Opti-MEM (Gibco, Invitrogen Life Technologies, UK) medium. After
incubation, complexes were added into 6-well plates followed by the addition of cells in
complete growth medium without antibiotics. The final concentrations of the p53-siRNA
(and negative control siRNA) were 30 nM and the volume of Lipofectamine™ RNAiMAX
was 5 μl/ well. The transfection time was 48 h, thereafter the medium was changed to
normal  growth  medium  and  cells  were  exposed  to  BP.  After  exposure,  total  cell  fractions
were prepared from the cells for immunoblotting.
4.7 STATISTICAL ANALYSIS (I-IV)
The data were analyzed with one-way analysis of variance (ANOVA) followed by Tukey’s
multiple comparison test. All statistics were performed with GraphPad Prism 4.03
(GraphPad Prism software, San Diego, CA). P values < 0.05 were considered as statistically
significant.
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5 Results
5.1 TP53 STATUS AND BENZO(A)PYRENE METABOLISM
5.1.1 TP53 mutations (III)
Exons 5-8 were sequenced to confirm the status of TP53 gene in different breast cancer cell
lines. The analysis was restricted to these exons encoding the DNA binding area of p53
protein  because  they  are  the  most  frequently  mutated  in  the  TP53  gene  (Hainaut  and
Hollstein, 2000). TP53 was also confirmed to be wild type (wt) in MCF-7 cells. ZR-75-1 cells
also contained a wt TP53. The other three cell lines (MDA-MB-231, MDA-MB-468, T47-D)
exhibited a mutation in the TP53 gene (Table 10).
Table 10. TP53 gene sequencing results of exons 5-8.
Cell line Mutation in exon Codon/Mut Amino acid change
MDA-MB-231 8 280: AGA > AAA Arg > Lys (R280K)
MDA-MB-468 8 273: CGT > CAT Arg > His (R273H)
T47-D 6 194: CTT > TTT Leu > Phe (L194F)
ZR-75-1a - - -
MCF-7a - - -
a wild type TP53
5.1.2 BPDE-DNA adducts (I, III)
BP  has  to  be  metabolized  before  it  becomes  mutagenic  and  carcinogenic  (Xue  and
Warshawsky, 2005). Previously (Rämet et al. 1995) it has been shown that MCF-7 and A549
cells  are  capable  of  metabolizing  BP  and  forming  BPDE-DNA  adducts.  The  BPDE-DNA
adduct formation in these cell lines was confirmed and it was noted that the amount of
adducts in A549 cells were low compared to MCF-7 cells (I) as shown before (Rämet et al.
1995). The formation of BPDE-DNA adducts was analyzed also in the four other breast
cancer cell lines. With the exception of the MDA-MB-231 cells, BPDE-DNA adducts were
formed in the other cell lines (III).
5.1.3 Reactive oxygen species (ROS) (II)
ROS  are  formed  endogenously  and  also  during  BP  metabolism  (Xue  and  Warshawsky,
2005). ROS have both genotoxic and non-genotoxic properties associated with tumor
formation.  A  statistically  significant  increase  in  ROS  levels  was  seen  after  48  h  of  BP-
treatment in MCF-7 cells (II).
5.2 THE EFFECTS OF BENZO(A)PYRENE
5.2.1 p53 protein (I, III)
In all of the breast cancer cell lines studied, except for MDA-MB-231 which contains a
mutated TP53, p53 was induced after BP treatment as shown by immunoblotting. The most
significant increase was detected in MCF-7 cells (I)  and  in  ZR-75-1  cells  (III)  which  both
have a wt TP53. A statistically significant increase was seen also in MDA-MB-468 and T47-
D cells although it was much weaker than in MCF-7 and ZR-75-1 cells.
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The effect of BP on p53 phosphorylation at several serine residues was also studied.
Different anti-phospho-53 antibodies were used in protein samples of MCF-7 cells to study
phosphorylation at Ser6, Ser9, Ser20, Ser37, Ser46 and Ser392 (I) and it was observed that
the most prominent serines being phosphorylated after BP-treatment were Ser20 and
Ser392. The studies were continued with serine 15 and 20 because they have been the most
commonly detected phosphorylations. Phosphorylation at serine 392 was also included
because it was so extensive in a screening study, and serine 46 which is associated with
apoptosis. In MCF-7 cells, the most prominent increase was seen in phosphorylation at
serine 392 after 24 h BP-treatment (I). In addition, serine 15 and 20 phosphorylations
increased after 48 h treatment to BP (I)  in  these  cells.  The  amount  of  phosphorylation  at
serine 46, on the other hand, was increased already after 24 h of BP treatment although
much less than that encountered at serine 392 (I).
The phosphorylations at serine 15, 46 and 392 of p53 protein were clarified in other breast
cancer cell lines (Table 11). Phosphorylation of p53 at serine 392 was most clear in ZR-75-1
cells with wt TP53, but also a statistically significant increase was seen in T47-D cells (III).
The increase in the amount of phosphorylation at serine 15 was statistically significant only
in MDA-MB-231 cells although an increase was seen also in MDA-MB-468 and T47-D cells
(III). A statistically significant increase in phosphorylation of serine 46 was seen only in
T47-D cells (III).
Table 11. TP53 status in different breast cancer cell lines, and formation of BPDE-DNA adducts
and effect on p53 induction and phosphorylation after benzo(a)pyrene treatment.
Cell lines
MDA-MB-231 MDA-MB-468 T47-D ZR-75-1 MCF-7
TP53 mut mut mut wt wt
BPDE-DNA adducts minor yes yes yes yes
total p53 no yes* yes* yes* yes
P-Ser6-p53 NS NS NS NS yes (48 h)
P-Ser9-p53 NS NS NS NS minor (48 h)
P-Ser15-p53 minor (48 h)* minor (48 h) yes (48 h) minor (48 h) yes (48, 72 h)
P-Ser20-p53 NS NS NS NS yes (48, 72 h)
P-Ser37-p53 NS NS NS NS yes (48 h)
P-Ser46-p53 minor (48 h) minor (48 h) yes (48 h)* minor (48 h) yes (24 h)
P-Ser392-p53 no no yes (48 h)* yes (48 h)* yes (24 h)*
*statistically significant increase
NS – not studied
Time points when phosphorylations were observed are in brackets.
5.2.2 Viability (I, II, III)
The effects of BP on cell viability were analyzed after treatment with different BP
concentrations at different timepoints (Table 12). MCF-7 cell viability was analyzed with
several methods, all of them confirming that BP induced cell death in these cells (I, II). In
ZR-75-1 cells, the results were rather similar: the viability started to decrease after 48 hours
of BP-treatment (III). The viability of MDA-MB-231 and T47-D breast cancer cells was not
changed, but in MDA-MB-468 cells there was a decline in cell viability after 48 hours of BP-
treatment (III).
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The relative cell number which is analyzed with PI-digitonin method revealed that BP had
an impact on cell proliferation. In MCF-7 and ZR-75-1 cells, the relative cell number
decreased already before any BP-induced cytotoxicity was observed; i.e. after 24 hours’ BP
treatment (I, III) and in other breast cancer cell lines, the relative cell number decreased
significantly after 48 hours’ BP-treatment (III)  as  compared to  control  cells.  In  all  five  cell
lines, 1 μM BP, which did not decrease cell viability, did evoke a decrease in relative cell
number evidence for an inhibition of cell proliferation (I, III).
Table 12. Viability after benzo(a)pyrene treatment in breast cancer cell lines analyzed using
different methods.
Cell line BP dose (µM) Time (h) Viability Method Publication
MCF-7 1, 5, 10, 20, 40 24 no effect PI-digitonin I
1, 5, 10, 20, 40 48 decrease PI-digitonin I
1, 5, 10, 20, 40 72 decrease PI-digitonin I
MCF-7 1, 2.5, 5 24 no effect Live gate II
1, 2.5, 5 48 decrease Live gate II
1, 2.5, 5 72 decrease Live gate II
MCF-7 1, 2.5, 5 24 no effect MTT (II)*
1, 2.5, 5 48 decrease MTT (II)*
1, 2.5, 5 72 decrease MTT (II)*
MCF-7 1, 2.5, 5 24 no effect PI exclusion** II
1, 2.5, 5 48 decrease PI exclusion II
1, 2.5, 5 72 decrease PI exclusion II
MCF-7 1, 2.5, 5 24 no effect Typan blue** (II)*
1, 2.5, 5 48 decrease Typan blue (II)*
1, 2.5, 5 72 decrease Typan blue (II)*
ZR-75-1 1, 2.5, 5 24 no effect PI-digitonin III
1, 2.5, 5 48 decrease PI-digitonin III
1, 2.5, 5 72 decrease PI-digitonin III
MDA-MB-231 1, 5, 10 48 no effect PI-digitonin III
MDA-MB-468 1, 5, 10 48 decrease PI-digitonin III
T47-D 1, 5, 10 48 no effect PI-digitonin III
*Results that are not shown in the original publication.
**Methods measure cell death.
5.2.3 Apoptosis (I, II)
It was interesting to study whether cell death caused by BP was apoptotic, indicating the
involvement of p53 protein. Apoptosis in MCF-7 cells after BP treatment was studied with
different methods (Table 13). The obtained results indicated that BP evoked apoptosis in
MCF-7 cell line although no caspase-3-like protease activity or internucleosomal DNA
fragmentation was seen (I). Caspase-7 immunoblotting revealed that this apoptotic protein
had  been  cleaved  to  its  active  form  in  MCF-7  cells  (I). This finding and flow cytometric
analysis showing that the subG1 fraction had been increased after BP treatment (II) are
evidence that BP-induced toxicity in MCF-7 cells was associated with apoptosis.
Further analysis of the apoptosis related proteins (PUMA-, cytochrome c) also indicated
that BP had triggered apoptosis and that this may be associated with p53 protein in MCF-7
cells (II). The PUMA- level  was  increased  and  cytochrome  c  was  released  from
mitochondria  to  cytoplasm  after  BP-treatment.  BP  increased  the  expression  of  PUMA-
protein also in ZR-75-1 cells, evidence that the BP-induced cell death had been apoptotic
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also in this cell  line (II).  The level of PUMA-, the function of which is unclear, decreased
after BP-treatment in both MCF-7 and ZR-75-1 cell lines (II).
Table 13. Apoptosis-related markers analyzed with different methods in MCF-7 cells after
benzo(a)pyrene treatment at different time points.
Cell
line
BP
dose
(µM)
Time (h) Target Result Method Publica-
tion
MCF-7 1, 5, 10,
20, 40
24, 48, 72 Caspase-3-like
protease activity
no effect Fluorometric
assay
I
MCF-7 1, 10 48, 72, 96 Internucleosomal
DNA fragmentation
no effect Electrophoresis I
MCF-7 5, 10 24, 48, 72 Caspase-7 cleaved caspase-7* Immunoblotting I
MCF-7 1, 2.5, 5 24, 48, 72 DNA content increase in subG1* Flow cytometry II
MCF-7 5 48 Cytochrome c release of
cytochrome c from
mitochondria
Confocal
microscopy
II
MCF-7 5 48 Cytochrome c increase of
cytochrome c in
cytosol
Immunoblotting II
MCF-7 5 (24), 48, 72 PUMA increase of PUMA- Immunoblotting II
MCF-7 5 48 BAX no effect Immunoblotting II
*effect not seen at the 24 h time point
5.3 p53 SUPPRESSION
5.3.1 The effect of PFT- and p53-siRNA (IV)
To further confirm whether p53 was important for BP-induced cell death, p53 was inhibited
by pifithrin-  (PFT-) or its translation was suppressed with p53-siRNA, in cells treated
with  BP.  The  effects  of  PFT- on  cell  viability,  and  the  expression  of  p53,  PUMA- and
PUMA- proteins were measured in MCF-7 and ZR-75-1 cells. PFT- prevented BP-induced
cell death almost completely but had no effect on the reduction in cell proliferation caused
by BP in MCF-7 cells.  According to the earlier study, BP caused cell  death in ZR-75-1 cells
(III).  However,  in  this  study  (IV) the viability did not decrease after BP treatment and
furthermore PFT- did not have any effect. The relative cell number was decreased, as in
the previous study (III), with BP but PFT- did not prevent this decline.
As anticipated, p53 protein was induced in MCF-7 cells after BP-treatment, and PFT-
inhibited the  induction in  a  statistically  significant  manner.  However,  PFT- did not have
any effect on PUMA- or PUMA- levels in these cells. In ZR-75-1 cells, PFT- did not alter
the levels of any of the proteins.
p53-siRNA inhibited the BP-induced p53 increase in MCF-7 cells. However, it did not exert
a statistically significant effect on PUMA- or PUMA- expression although the trend
observed in protein expression did support the earlier findings (II) suggesting that p53
protein is involved in BP induced cell death.
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6 Discussion
6.1 EVALUATING THE MECHANISMS OF TOXICITY
Chemical substance
In studies on the mechanisms of carcinogenicity, it is important to consider whether the
substance is a direct carcinogen or an indirect carcinogen, requiring metabolic activation
before it can exert its harmful effects. BP is an indirect carcinogen and cytochrome P450
enzymes are involved in its metabolism. In particular, CYP1A1 and CYP1B1 are involved in
the production of reactive metabolites of BP (e.g. Gelboin, 1980; Pelkonen and Nebert,
1982). It has been shown earlier (Rämet et al. 1995) and also in the present study (I) that
MCF-7 cells are able to metabolize BP to BPDE and form DNA-adducts. Three of the other
used breast cancer cell lines (ZR-75-1, T47-D, MDA-MB-468) studied here were able to
metabolize  BP  to  BPDE  and  form  DNA  adducts  as  well  (III). Only in MDA-MB-231 cells
were  minimal  amounts  of  DNA-adducts  formed  (III). CYP1A1 and CYP1B1 enzymes are
predominantly expressed in extrahepatic tissues, e.g. lung and breast. Thus, it has been
speculated  that  the  expression  level  and  activity  of  these  enzymes  in  the  tissues  can  be
responsible for the differences in the susceptibility to lung and breast cancer after BP
exposure (for a review, see Shimada, 2006). In addition, one has to take into account the fact
that in a mixture of PAHs, other PAHs may enhance or suppress the metabolic activation of
carcinogenic PAHs thus affecting both toxicity and carcinogenicity (Shimada et al. 1996;
Kim et al. 1998; Willett et al. 1998; Spink et al. 2002; Shimada and Guengerich, 2006).
Dose is always an important factor when planning toxicological studies. In general the
following  BP  concentrations  were  used  in  this  study:  1,  2.5,  5  and  10  μM.  Cell  culture
studies indicated that 10 μM BP was quite toxic to the cells. Furthermore, compared to the
levels encountered in environmental exposure to BP, even the lowest concentration in these
studies  (1  μM)  was  far  higher  than  the  concentrations  of  BP  found  in  food  and  water
(Jakszyn et al. 2004; Lee and Shim, 2007). Nevertheless, these rather high concentrations
were used in our experiments in order to obtain molecular responses within short exposure
times (24, 48 and 72 h). BP-metabolism also produces several metabolites whose
concentrations are lower than the concentration of parent compound which justifies the
used BP concentrations in these studies.
Cell models
In addition to functional BP-metabolism, MCF-7 cells also have wild type TP53, and this
protein is induced after BP-treatment (Rämet et al. 1995; I). Both of these features are
essential in studies evaluating the effect of BP on the p53 pathway and related cellular
apoptosis.  For  this  reason  the  MCF-7  cell  line  was  chosen  as  the  main  model  and  the
reference cell line in this project to which also BP-induced responses in other breast cancer
cell lines (MDA-MB-231, MDA-MB-468, T47-D, ZR-75-1) were compared.
Cell lines, particularly cancer cell lines are widely used in scientific research. They have
both advantages and disadvantages (Burdall et al. 2003). The advantages include their ease
of handling, unlimited replication, a relatively high degree of homogeneity and that they
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are easily grown from frozen stock. On the other hand, they are prone to genotypic and
phenotypic drift during culture. There are also variations in cell growth rate and changes in
hormone receptor content. Over the years, many breast cancer cell lines have been
established, the first one already in 1958. Many of the currently used cell lines were initially
described in 1970s and only a few of them are in wide use, e.g. MCF-7, T47-D and MDA-
MB-231 (Lacroix and Leclercq, 2004).
Before one can evaluate p53-mediated responses after BP treatment in different breast
cancer  cell  lines,  it  is  important  to  determine  the  status  of  the  TP53  gene.  About  97  %  of
TP53 mutations are located in the DNA binding domain (Hainaut and Hollstein, 2000;
Olivier et al. 2002; McKinney and Prives, 2007). As expected, no mutations were detected in
exons 5-8  of  TP53 in  MCF-7 cell  line  (III). This is accordance with earlier studies showing
that MCF-7 cells have wt TP53 (O’Connor et al. 1997). In addition, ZR-75-1 contained wt
TP53 while the other studied cell lines (MDA-MB-231, MDA-MB-468, T47-D) had mutated
TP53 (III). Although these mutations were known from the literature (Runnebaum et al.
1991; Avila et al. 1994; O’Connor et al. 1997) and ATCC (American Type Culture Collection)
it was important to ensure that the TP53 status in the cells used here was the same as that
previously described.
There has been a vigourous debate about how well breast cancer cell lines represent breast
cancer or even normal breast tissue. Most of the breast cancer cell lines have been isolated
from cancer metastasis, or aspirates of pleural effusions, not from the primary tumor
(Burdall et al. 2003; Lacroix and Leclercq, 2004). Cells from primary tumors may be
clinically more relevant than those originating from metastatic sites. As mentioned before,
cancer cell lines are genetically unstable and for this reason cell lines, e.g. MCF-7, which
have been distributed throughout the world may have changed their properties and
produced distinct sub-populations in different laboratories (Burdall et al. 2003; Lacroix and
Leclercq, 2004). It is clear that freshly isolated cells represent best the tumor in vivo and
prolonged culturing may alter the properties of the cells. It is known that different breast
cancer cell lines display different phenotypes, e.g. estrogen receptor  positive/ERBB2
negative cell lines MCF-7 and T47-D which may model certain types of breast tumors in
vitro. In addition to MCF-7 cells, four different breast cancer cell lines were investigated
that  represent  different  phenotypes.  It  was  hoped  that  by  comparing  the  responses  to  BP
between the cell lines, this would help to clarify whether the effects are cell line specific or
breast tissue specific.
6.2 p53 RESPONSES IN HUMAN BREAST CANCER CELL LINES AFTER
BENZO(a)PYRENE TREATMENT
p53 protein
As anticipated, the levels of p53 were elevated after BP treatment in MCF-7 and ZR-75-1
cells  containing  wt  TP53  (I, III). However, in two cell lines (MDA-MB-468 and T47-D)
where the TP53 gene was mutated, an increase in total p53 was also found (III).  This may
be due to the inability of mutated p53 to activate MDM2 which is involved in p53
degradation (Hainaut and Vähäkangas, 1997; Haupt et al. 1997; Vousden and Lu, 2002). In
addition, phosphorylation at MDM2 binding site (residues 18-23) has been reported to
inhibit MDM2-mediated p53 degradation (Lavin and Gueven, 2006). There was no evidence
of p53 protein induction in MDA-MB-231 cells which is probably attributable to the
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mutated TP53 (III). The minor BPDE-DNA adduct formation may also have been
influenced by the lack of p53 response in these cells.
It is well known that the level of p53 protein is increased after many types of genotoxic
exposures (Kurihara et al. 2007; Liu et al. 2008; Pääjärvi et al. 2008; Cox and Meek, 2010;
Lüpertz et al. 2010; Banu et al. 2011; Mukherjee et al. 2011) in various experimental settings
(primary and secondary cells, animals). BP causes p53 induction in vitro in cell lines (Rämet
et al. 1995; Holme et al. 2007; Topinka et al. 2008; Al-Anati et al. 2010) and in vivo in animal
tissues (Bjelogrlic et al. 1994; Tapiainen et al. 1996; Serpi et al. 1999). Many of the in vitro
studies  have  been  conducted  with  rodent  cell  lines  although  human  cells  would  be  more
relevant  in  the  toxicity  and mechanistic  studies  of  BP on humans.  The difference  between
animal and human cells in p53 phosphorylation was clearly demonstrated by this study (I).
In addition, comparison of the results between cells from same origin, e.g. breast, lung or
liver, probably gives more accurate data of the responses of the tissue to a certain
treatment.
Phosphorylation
In order to be active, p53 has to be post-translationally modified. Phosphorylation of serines
15 and 20 stabilizes p53 protein by repressing the interaction of p53 and MDM2 (Shieh et al.
1997; Unger et al. 1999). However, in MCF-7 and ZR-75-1 cells, increased amounts of
phosphorylation at serine 392 were the most prominent modification, suggesting that it is
probably the first stabilizing event occurring after BP treatment in these cells (I, III). The
results of earlier studies on the function of phosphorylation at serine 392 are contradictory.
It has been shown that the phosphorylation of serine 392 is not required for p53 to act
normally in the regulation of cell growth or transcription activation (Fiscella et al. 1994). On
the other hand, it has been claimed that this modification increases the tetramerization in
vitro leading to p53 stabilization (Sakaguchi et al. 1997) and it can enhance the sequence-
specific DNA-binding and transcription activity of the cells after UV-exposure (Keller et al.
2001). Recently, phosphorylation of serine 392 has been shown to be an important
modification encountered in p53 after several stress responses, e.g. UV, IR and etoposide
(Cox and Meek, 2010).
Although there are no other studies investigating BP-induced phosphorylation of p53 at
serine 392, there are instancess where an increase of serine 392 phosphorylation has
occurred after different exposures. For example, Cox and Meek (2010) have shown that
treatments with etoposide, Nutlin 3a (MDM2 inhibitor), UV and IR of U2OS (human
osteosarcoma) and MCF-7 cells induced serine 392 phosphorylation of the p53 protein.
They also suggested that this modification occurred independently of the stimulus by
which p53 had been induced. Thus, these results support an important role for
phosphorylation at serine 392 in p53 stabilization.
Phosphorylation of serine 46 is important for p53-dependent apoptosis as has been shown
in cell culture studies (Oda et al. 2000; Yoshida et al. 2006) and in mice (Feng et al. 2006).
Clear evidence of phosphorylation at serine 46 was found in MCF-7 and T47-D cells
suggesting that BP was able to induce apoptotic cell death in these cell lines (III). In the
MCF-7 cell line with wt TP53, this may be true but in T47-D cells with the mutated TP53 the
consequence of this modification is not completely clear. However, Kurihara et al. (2007)
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proposed that phosphorylation of serine 46 does not always lead to apoptosis or induction
of apoptotic genes, e.g. AIP1 (apoptosis inducing protein 1). They reported that adriamycin
did not trigger apoptosis in four senescense-sensitive cell lines (TIG1, TIG3, A549, MCF-7)
even though serine 46 had been phosphorylated.
Research on phosphorylation of mutant p53 has provided conflicting results (for a review,
see Matsumoto et al. 2006) although it is believed that phosphorylation of mutant and also
wt p53 are altered in carcinogenesis, and furthermore that phosphorylation of mutant p53
is an important process in tumor development (Bode and Dong, 2004; Matsumoto et al.
2006). In the present studies, the increase in the amount of phosphorylation at serine 392 of
mutated p53 was found in T47-D cells. However, the level of this phosphorylation was
quite  high  already  in  control  cells  as  was  found  also  in  other  cell  lines  with  mutated  p53
(MDA-MB-231, MDA-MB-468; III). The high level of phosphorylated p53 in untreated cells
may support the hypothesis of Matsumoto et al. (2006) that phosphorylation of mutant p53
at serine 392 is related to dominant-negative effects thus contributing to carcinogenesis.
6.3 APOPTOSIS IN BENZO(a)PYRENE-INDUCED TOXICITY
Cell  death  is  one  indication  of  the  cytotoxicity  evoked  by  different  chemicals.  Apoptosis,
which  is  one  form  of  cell  death,  can  occur  through  multiple  pathways  which  makes  it  a
very challenging study subject. In order to confirm that cell death is actually apoptotic, one
has to analyze the situation with complementary methods. Several studies have shown that
BP can trigger apoptosis in different cell lines (Ko et al. 2004; Solhaug et al. 2005; Holme et
al. 2007; Yang et al. 2011). Several apoptotic parameters were analyzed after BP treatment to
clarify if BP caused apoptosis in the MCF-7 cell line. PUMA- increase, caspase-7 cleavage
and cytochrome c release indicate that the cell death caused by BP was apoptotic, although
no evidence was found for caspase-3-like activity and internucleosomal DNA
fragmentation. Thus, BP probably evokes apoptotic cell death in MCF-7 and probably also
in ZR-75-1 cells (I, II). However, necrosis, the other form of cell death cannot be ruled out in
this case. High concentrations of BP are very cytotoxic to cells and an overwhelming BP
exposure may lead to necrotic cell death. Ovrevik et al. (2010) studied the effects of
different  PAHs in  human bronchial  epithelial  cells  (BEAS-2B)  and come to  the  conclusion
that high concentrations of BP (15 and 30 μM) induced necrosis instead of apoptosis in
these cells.
PUMA and Bax
PUMA protein is recognized as an important protein in DNA damage-induced apoptosis
(Vousden, 2005; Wang et al. 2007). After DNA damage, it is induced by p53-dependent
transcription, although a p53-independent transcription mechanism also exists (Yu and
Zhang, 2009). PUMA- and PUMA- are the functional isoforms of the protein (Nakano
and Vousden, 2001). Generally, the studies dealing with induction of PUMA in apoptosis
do not define which of the PUMA isoforms has been analyzed. In this study, it was found
that PUMA- was induced after BP treatment in MCF-7 and ZR-75-1 cells (II) suggesting
that the PUMA- form is  involved in  BP induced apoptosis.  It  was  also  observed that  the
PUMA- isoform was down-regulated after BP treatment. Concurrent induction of PUMA-
 and down-regulation of PUMA- has been also shown by Solé et al. (2008) and Sanz et al.
(2008) although in other cell lines and with different treatment protocols. PUMA induction
by BP is in accordance with Yang et al. (2011) who reported in human fetal lung fibroblasts
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(MRC-5) that the expressions of caspase-9, caspase-3 and PUMA were up-regulated by BP
at the mRNA level, with PUMA expression being the most prominent of these responses.
Bax protein is involved in the permeabilization of mitochondrial outer membrane
(Breckenridge and Xue, 2004) and its activity is also regulated by p53 protein at both
transcription-dependent and transcription-independent levels (Chipuk and Green, 2006).
Interestingly, Neise et al. (2008) concluded that Bax and Bak were involved in the activation
of the mitochondrial death pathway and furthermore that after staurosporine, actinomycin
D and TRAIL treatment activation of Bak in MCF-7 cells occurred prior to activation of Bax.
In caspase-3-deficient MCF-7 cell line they also found evidence for reduced activation of
Bax (Neise et al. 2008). Thus, it was decided to examine whether the expression of Bax
would be increased in the mitochondrial fraction after BP treatment but no evidence for any
change in the expression of Bax was found between mitochondrial and cytoplasmic
fractions in MCF-7 and ZR-75-1 cells (II).
Cytochrome c and caspases
The formation of a pore on mitochondrial outer membrane triggers cytochrome c release
from mitochondria into cytoplasm (Elmore, 2007; Orrenius et al. 2011; Ola et al. 2011). The
induction  of  p53  protein  (I)  and  the  release  of  cytochrome  c  (II)  indicate  that  BP  induced
apoptosis had occurred through the mitochondrial-mediated apoptotic route. However,
MCF-7 cells lack caspase-3 activity because of a functional deletion of the CASP-3 gene
(Jänicke et al. 1998). Accordingly, in the analysis of caspase-3-like protease activity after BP
treatment no activity was found (I). Caspase-3 activity is also needed for internucleosomal
DNA fragmentation, accounting for the lack of DNA fragmentation after BP treatment.
However, it has been proposed that caspase-7 may also be responsible for DNA
fragmentation (McGee et al. 2002) but the process is much slower in MCF-7 cells as
compared to cells having a functional CASP-3 gene (Twiddy et al. 2006). Thus, it was
decided to determine whether caspase-7 was involved in cell death and evidence was
found for cleavage of caspase-7 (I)  pointing  to  a  role  for  this  enzyme  in  BP-induced  cell
death (see figure 12).
Inhibition of p53 protein
To further confirm the finding that BP induced p53-mediated apoptosis in MCF-7 cells, p53
protein was inhibited by exposure to a specific inhibitor, PFT- (IV). PFT- prevented BP-
induced cell death supporting the finding that p53-mediated apoptosis is, at least partly,
involved in toxicity of BP. Solhaug et al. (2005) reported that PFT- inhibits BPDE-induced
apoptosis in Hepa1c1c7 (mouse hepatoma) cell line probably in a p53-dependent manner.
In addition, Sadikovic and Rodenhiser (2006) who studied the combined effects of BP and
PFT- on  MCF-7  cells,  proposed  that  p53  was  involved  in  BP-induced  cell  death  in  these
cells. On the other hand, Sparfel et al. (2006) claimed that PFT- inhibits the activity of
cytochrome P450 enzymes, e.g. CYP 1A1 and 1B1 thus preventing the metabolism of BP.
They detected diminished BPDE-DNA adduct  formation and apoptosis  pointing to  a  p53-
independent action of PFT- (Sparfel et al. 2006). The possibility that PFT- had affected on
BP metabolism and BP-induced cell death in the present study cannot be ruled out; this
maybe an alternative explanation for the present results. p53 translation was suppressed by
p53-siRNA in MCF-7 cells and decreased expression of p53 protein was detected after BP
treatment (IV). This same effect was seen also in the study of Mukherjee et al. (2011) who
investigated the effect of BPDE in mouse epidermal JB6 cells transfected by p53-siRNA.
51
However,  in  this  study  p53-siRNA  did  not  have  any  effect  on  BP-induced  cell  death,
possibly because the fully functional remaining p53 induced cell death in the BP-treated
cells.
Figure 12.  Summary  of  the  apoptotic  pathway  triggered  after  BP  exposure  in  MCF-7  breast
cancer cell line.
p53  is  a  tumor  suppressor  protein  which  responds  to  many  cellular  stressors,  e.g.  DNA
damage, oncogenes and viruses (Guimaraes and Hainaut, 2002; Hussain and Harris, 2006;
Högberg et al. 2009). However, it is not a specific marker of genotoxicity. The present work
analyzed BPDE-DNA adducts from the studied cell lines (I, III)  and the  induction of  p53
protein as a marker for genotoxicity of BP. In an attempt to clarify the downstream effects
of p53 induction the apoptotic markers of BP-induced cell death were examined. Apoptosis,
which may be one way to protect organisms from the genotoxic effect of BP, is an indication
that  BP  (and  PAHs)  induces  harmful  cellular  effects  and  may  be  involved  in  the  breast
carcinogenesis (see figure 12).
6.4 FUTURE PLANS
It  is  a  fact  that  humans  are  exposed  to  numerous  chemicals/substances  throughout  their
lifespan. PAHs are a ubiquitous group of compounds that have harmful effects on human
health. In particular, tobacco smoke is a major source of exposure to PAHs. Tobacco smoke
is known to contain at least 60 carcinogenic compounds (IARC, 2004; Wogan et al. 2004).
Even though there are only clues that exposure to PAHs is one of the risk factors for breast
cancer, there are in vivo and in vitro experiments (including the present) that point to a role
for PAHs in breast carcinogenesis. The other chemicals in tobacco smoke most likely affect
the  carcinogenicity  of  PAHs.  Nicotine  has  been  shown  to  have  capability  to  induce  cell
proliferation and repress  DNA damage-induced apoptosis  (for  a  review,  see  Catassi  et  al.
2008)  thus  having  a  role  by  increasing  the  carcinogenicity  of  DNA  damaging  agents.  By
examining the combined effects of BP and nicotine one could gain further insights into the
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process of breast carcinogenesis after inhalation of cigarette smoke in humans. Currently
even young adolescent girls are using alcohol frequently, and in increasing amounts.
Because alcohol has been epidemiologically proven to cause breast cancer, the
simultaneous use of alcohol and tobacco smoking, a habit which is also becoming more
popular  in  young  girls,  would  be  anticipated  to  have  harmful  combined  effects  on  breast
development. Studies on the combined effects on alcohol and BP would also provide new
insights into breast carcinogenesis.
In addition, many other chemicals, e.g. polychlorinated biphenyls (PCBs), metals and
drugs, have adverse effects on human health. The cellular effects of combined exposures of
such substances are still largely unknown. In the literature, there are studies showing that
combined effect of BP and other exposures (e.g. UVA, cadmium and 3,3’,4,4’,5-
pentachlorobiphenyl) can have additive carcinogenic effects (Burke and Wei, 2009; Costa et
al. 2010; Wei et al. 2009). Therefore, combining BP with other chemicals in experimental
studies will be necessary in order to elucidate the cellular and molecular effects and their
impact on human health.
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7 Summary and Conclusions
1. Studies on the effect of BP on breast carcinogenesis have to be carried out in well
characterized human cell lines. Even though in vivo experiments in animals give
large amount of information about the effects of BP, mechanistic studies conducted
in  cell  lines  complement  the  results  obtained  in  vivo.  A  comparison  of  the  results
from several cell lines clearly provides more information than can be obtained from
a single cell type. In our studies on the mechanisms of BP in human breast cancer cell
lines, the results were different from those gained in animal cell lines as reported in
the literature. In addition, the properties of the cell lines related to the particular
study have to be known, e.g. in our case their metabolic capacity and TP53 status.
Four of five breast cancer cell lines we studied were able to metabolize BP to its
carcinogenic diol epoxide form as confirmed by the presence of BPDE-DNA adducs
in these cells. Only two cell lines (MCF-7 and ZR-75-1) contained wt TP53 which is
the prerequisite for the studies on p53 pathway. Thus these two cell lines are useful
if  one  wishes  to  examine  the  mechanisms  involved  in  the  toxicity  of  BP  in  human
breast cells.
2. It is probable that BP exposure leads to p53 phosphorylation at serine 392 in human
breast tissue. Post-translational modifications of p53 were analyzed and it was noted
that phosphorylation at serine 392 was the first stabilizing modification occurring
after BP treatment in MCF-7 cell lines, although also other p53 phosphorylations
were observed. The same effect, although much weaker, was seen also in ZR-75-1
cell line. In the other cell lines (MDA-MB-231, MDA-MB-468 and T47-D) containing
mutated TP53 no clear evidence of phosphorylation at serine 392 was seen. In
conclusion, p53 is phosphorylated at serine 392 after BP treatment in a human breast
cancer cell lines containing wt TP53.
3. BP induced cell death in human breast cancer cell lines was confirmed to be
apoptotic  in  MCF-7  and  possibly  in  ZR-75-1  cells,  since  the  level  of  PUMA-
expression was increased, cytochrome c was released from mitochondria and
caspase-7 was cleaved. However, the possibility of necrosis could not be ruled out
when using high concentrations of BP. It seems that apoptosis is the final attempt of
cells to prevent the harmful effects of BP, should the cell cycle arrest and DNA repair
have failed.
4. This work implicates a role of PAHs, which are ubiquitous environmental
contaminants, in the etiology of human breast cancer. This conclusion is supported
by all the data collected i.e. the formation of BPDE-DNA adducts, the induction and
activation of p53 protein, and the evidence of apoptosis. These results are in
agreement with the literature reporting that after BP exposure, BPDE-DNA adducts
are found in vivo breast tissue and mammary tumors are formed in animals.
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Polycyclic aromatic hydrocarbons 
(PAHs), like benzo(a)pyrene (BP), 
are carcinogenic compounds present 
in tobacco smoke, which may 
increase the risk of breast cancer. 
Human breast cancer cell lines were 
characterized and BP-induced p53-
mediated responses protecting from 
the carcinogenic effects of BP in 
these cell lines were studied. The 
hypothesis that exposure to PAHs is 
one of the risk factors for breast cancer 
is supported by the formation of BP-
diolepoxide-DNA adducts, induction 
and activation of p53 protein  and the 
evidence of apoptotic cell death after 
BP-treatment. 
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